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Each  year  there  are  more  than  250  million  cases  of  malaria,  claiming  nearly  one  113 
million  deaths  of which most  are  among  children  below  the  age  of  five  from  sub‐ 114 
Saharan  Africa.  An  effective  malaria  vaccine  could  prove  to  be  the  most  cost‐ 115 
effective  and  efficacious  means  of  preventing  severe  disease  and  death  from  116 
malaria. To date, no approved malaria vaccine is available and only a few candidate  117 
vaccines  were  able  to  induce  some  protective  efficacy.  Limited  success  in  the  118 
development of a malaria vaccine may partly be due to the reliance on a hand full of  119 
antigens discovered more than 20 years ago. Since the fully annotated Plasmodium  120 





selection  of  hypothetical  surface  proteins  of  extracellular  parasite  stages  and  126 
subsequent functional characterization using specific monoclonal antibodies.   127 
Functional  in vitro  and  in vivo  assays  require antibodies capable of  recognizing  the  128 
endogenous  antigen  in  its  native  context.  We  developed  an  entirely  cell‐based  129 
approach  that bypasses  the problematic  step of protein purification. By presenting  130 
the  antigen  on  the  surface  of  mammalian  cells  in  its  native  conformation  for  131 
immunisation and hybridoma selection,  this procedure promotes the generation of  132 
monoclonal antibodies capable of binding to the native endogenous target proteins.  133 
This  was  exemplified  by  three  hypothetical  surface  proteins  of  P.  falciparum,  134 









cell‐cell  interactions,  in  gametocytes  and  sporozoites.  Both  proteins  await  further  141 
investigation in assay systems assessing sporozoite and sexual blood stage inhibition.  142 
A third candidate, designated cysteine‐rich protective antigen (CyRPA), is expressed  143 







The  in vivo  growth  inhibitory effect of antibodies  specific  for malaria P.  falciparum  151 
blood  stage  antigens  was  assessed  by  passive  immunisation  experiments  in  P.  152 
falciparum  infected NOD/scid‐IL2Rγnull mice  engrafted with human erythrocytes.  In  153 
contrast to previously described passive  immunisation studies  in other SCID mouse  154 
lines, this model evinced a dose‐response relationship. Thus we propose this model  155 
for  comparison  of  the  relative  in  vivo  inhibitory  potency  of  malaria  specific  156 
antibodies.  157 
Applying  the  principle  of  reverse  vaccinology,  we  identified  and  characterized  158 
surface  proteins  of  extracellular  malaria  stages.  Thereby  we  identified  CyRPA  as  159 
target of merozoite  invasion‐inhibitory antibodies. We expect  that  characterization  160 
of  further  hypothetical  parasite  proteins  with  this  strategy  will  identify  additional  161 
vaccine  candidate  antigens  from  the extracellular  stages of  P.  falciparum.  This will  162 







Even  though  we  only  realize  it  once  we  lost  it,  good  health  is  one  of  the  most  167 
important dimensions of our quality of  life. Besides, health  is a major  resource  for  168 
social,  economical  and  personal  development  [1].  In  the  Universal  Declaration  of  169 




diseases. Globally, malaria  is placed on  rank 12 of  the  leading causes of burden of  174 
disease.  It  is  responsible  for  2.2%  of  total  DALYs  (disability‐adjusted  life  years),  a  175 
measure that combines years of life lost due to premature mortality and years of life  176 
lost due to time lived in states of less than full health or disability into a single metric  177 
[3].  Restricted  to  sub‐Saharan  Africa,  malaria  claims  8.2  %  of  total  DALYs,  being  178 
number four after HIV/AIDS, lower respiratory infections and diarrhoeal diseases [4].  179 
Malaria mainly affects  children and  is  responsible  for 16% of  the  total mortality  in  180 
African children below the age of five [5].  181 
According to the WHO, malaria occurs in 108 countries, mainly in sub‐Saharan Africa,  182 
but  also  in  Asia,  Oceania,  Central  and  South  America,  and  the  Caribbean.  183 
Approximately 40% of the world population (3.3 billion people) are at risk [6]. Each  184 
year malaria  causes 250 million  cases,  claiming nearly one million deaths of which  185 
most are children below the age of 5 or pregnant women from sub‐Saharan Africa  186 
[6].  In  some  heavy‐burden  countries,  malaria  accounts  for  30‐50%  of  all  hospital  187 
admissions  and  is  responsible  for  up  to  40%  of  public  health  expenditures  [7].  188 
Malaria  particularly  affects  poor  people  who  cannot  afford  treatment  and  have  189 
limited access to health care [8,9]. Hence, malaria brings about a downward spiral of  190 





Malaria  is  transmitted exclusively  through the bite of Anopheles mosquitoes. Thus,  193 




Malaria  is  caused  by  protozoal  endoparasites  of  the  genus  Plasmodium.  Human  198 
malaria can be caused by infection of five different malaria species; P. falciparum, P.  199 
vivax,  P.  malariae,  P.  ovale  and  P.  knowlesi.  P.  falciparum  is  the  most  deadly,  200 
accounting for 92 % of all cases [11].  201 
P. falciparum life cycle  202 
The  life  cycle  of  P.  falciparum  involves  an  alternation  of  asexual  and  sexual  203 
generations  and  obligatory  heteroecism  between  Homo  sapiens  and  Anopheles.  204 
Parasites  are  transmitted  to  the  human  host  by  the  bite  of  infected  mosquitoes.  205 
During the blood meal, sporozoites, the fusiform infectious stage, are inoculated into  206 
the  human  skin  and  reach  the  liver  via  the  blood  circulation,  where  they  infect  207 
hepatocytes.  Within  6  days  the  parasites  develop  into  multinucleated  schizonts,  208 
from which up to 30’000 1.5 μm long ovoid cells, called merozoites, are formed. The  209 
rupture of the infected hepatocyte releases merozoites into the bloodstream. Within  210 
1‐2  min  of  release,  merozoites  attach  to  specific  receptors  on  the  surface  of  211 
erythrocytes,  which  initiates  active  invasion  into  the  erythrocyte.  Within  a  212 
parasitophorous  vacuole,  the  parasite  undergoes  maturation  into  ring‐stages,  213 
trophozoite‐stages  and  upon mitotic  division  into  schizont‐stages.  8‐32 merozoites  214 
are formed from each schizont, which, upon rupture of the erythrocyte, are released  215 
into  the  blood  stream,  where  each  one  starts  a  new  asexual  cycle  by  infecting  216 
another erythrocyte.  In the case of P. falciparum  the asexual cycle takes 48h. After  217 
repeated asexual cycles, some parasites develop into sexual stages. Male and female  218 
gametocytes  persist  in  the  blood  for  up  to  22  days. When  taken  up  by  a  feeding  219 
mosquito, the male gametocytes exflagellate into 8 single‐nucleated microgametes,  220 
which fertilize female macrogametes. Gamete fusion  induces formation of a motile  221 




develops between  the epithelium and  the basal  lamina  into  an oocyst.  The oocyst  223 
undergoes  schizogony  leading  to  the  formation  of  thousands  of  sporozoites.  224 
Eventually  oocysts  rupture  and  freed  sporozoites  travel  via  the hemolymph  to  the  225 





clinical  symptoms  develop  not  until  7  days  after  the  infectious  mosquito  bite.  231 
Severity  of  the  disease  depends  largely  on  the  infecting  species  and  the  232 
immunological  status  of  the  affected  person.  Particularly  susceptible  are  non‐ 233 
immune humans from malaria non‐endemic areas as well as children of the age of 6  234 
months  to 3  years  living  in  endemic  countries.  Initial  symptoms are  fever,  nausea,  235 
headache,  muscular  pain  and  chills  and  describe  uncomplicated  malaria.  P.  236 




Malaria  is  treated  by  oral  drugs  including  chloroquin,  mefloquin,  and  artemisinin.  241 
However,  resistance  to  chloroquin  and  sulfacoxine‐pyrimethamine  has  spread  to  242 
large geographical areas [13]. This leaves artemisinin‐based combination therapy as  243 
the best  available  treatment option  [14]. Prophylactic  chemotherapy  is  applied  for  244 
non‐immune travellers to endemic areas. Exposition prophylaxis  is achieved by bed  245 
nets, insect repellents, appropriate clothing, or vector control by insecticide‐treated  246 
bed nets and  indoor residual spraying of  insecticides. Vector control was shown to  247 







ages.  In  contrast,  in  highly  endemic  areas,  the  incidence  of  severe malaria  largely  252 
depends  on  the  age  of  the  host  [16].  In  newborns,  the  prevalence  of  parasitemia  253 
increases  sharply  at  about  20  weeks  of  age  but  the  infants  remain  more  or  less  254 
resistant to high parasitemia, fever and severe disease until about 6 months of age.  255 
For the next one to two years, risk of severe malaria increases rapidly, followed by a  256 
gradual decrease  till  the age of 5. Although  largely protected  from severe disease,  257 
children  remain  susceptible  to  uncomplicated  malaria  episodes  till  they  reach  258 
adolescence.  Adults  living  in  high  endemic  countries  rarely  experience  malaria  259 
episodes  but  may  remain  infected.  Parasite  density  gradually  decreases  with  age  260 
[17,18]. Protection against disease  is  lost  if a person moves to a non‐endemic area  261 
[19].  262 
Protection of adults is mediated by natural immunity. This immunity protects against  263 
symptomatic  disease,  death  and  high‐density  parasitemia,  but  is  not  effective  in  264 
offering  sterile  immunity.  The  rate  at which  immunity  is  acquired  correlates  upon  265 
the degree of exposure [20]. In addition, the acquired protection is short lived and its  266 
maintenance is dependent on sustained exposure [21]. Protection  in  infants till  the  267 
age  of  6  moths  is  possibly  associated  with  fetal  hemoglobin  and  the  presence  of  268 
maternal  immune  immunoglobulin  acquired  from  the  immune mother  in  utero  or  269 
from breast milk [22,23].  270 
Naturally  acquired  immunity  predominantly  targets  the  asexual  blood  stages  [21].  271 
No protection against pre‐erythrocytic stages is acquired. This is evident by the fact  272 
that  adults  living  in  malaria‐endemic  areas  cleared  from  parasites  are  readily  273 
reinfected  and  reinfection  rates were  shown  to  be  identical  for  adults  and  infants  274 
[24].   275 















efficiently  eliminate  liverstage  parasites  [32].  CSP  was  identified  as  the  288 
immunodominant  protein  involved  in  T‐cell  mediated  protection  induced  by  289 
immunization with sporozoites [33]. Furthermore it was shown that IFN‐γ is a critical  290 
effector molecule, that  IL‐4 secreting CD4+ T cells are required for  induction of the  291 
CD8+  T  cell  responses,  that  Th1  CD4+  T  cells  provide  help  for  optimal  CD8+  T  cell  292 
effector activity and that components of the  innate  immune system,  including γδ T  293 
cells, natural killer cells and natural killer T cells, also play a role [34]. However, it is  294 
important to note that exposure by natural transmission does not induce protective  295 
immunity  to  infection.  Naturally  exposed  individuals  harbour  few  numbers  of  296 
circulating  CD8+  T  cells  specific  for  parasite‐derived  epitopes  [35,36].  But  it  is  not  297 
clear if these CD8+ T cells have any anti‐parasite activity and if they contribute to the  298 
immunity acquired with age in individuals of malaria endemic areas.  299 
Antibody‐independent  cell‐mediated  immunity  was  also  found  to  have  a  role  in  300 
blood stage immunity. It was shown that mice lacking B cells and antibodies are able  301 
to control blood stage infection [37,38]. However, the relative importance of cellular  302 
or  humoral  immunity  was  found  to  vary  among  different  rodent  malaria  models  303 




T‐cell  activation  like  IL‐12,  IFN‐γ  and  TNF‐α  [44].  The  presence  of  IFNγ  and  TNFα  308 







and  drug  cure  induced  protective  immunity  characterized  by  the  presence  of  a  313 
proliferative  T‐cell  response,  involving  CD4+  and  CD8+  T  cells,  IFNy  response  and  314 
induction of high concentrations of nitric oxide synthase activity in peripheral blood  315 
mononuclear cells  [47]. Less  is known about the contribution of T‐cells to naturally  316 
acquired  protection  in  humans.  Cell  mediated  immunity  is  not  readily  induced  by  317 
natural  infection  in  humans  [48].  However,  IFNy‐secretion  and  high  proliferative  318 
responses  to  blood  stage  antigens  were  shown  to  be  associated  with  clinical  319 
protection [48–50].  320 
An  important  role  for  antibodies  in  malaria  immunity  has  been  demonstrated  by  321 
passive immunisation studies in humans [51,52]. Serum antibodies of immune adults  322 
transferred  to  non‐immune  individuals  suffering  from  severe  clinical  malaria  323 
conferred  a  rapid  drop  in  parasitemia  and  cease  of  symptoms  [51,52].  Antibodies  324 
induced by P.  falciparum  infection are mainly directed against asexual blood  stage  325 
antigens  and  are  specific  for  proteins  expressed  on  the  membrane  of  infected  326 
erythrocytes,  the surface of extracellular merozoites, or  for proteins  released  from  327 
secretory  organelles  upon  invasion.  Various  mechanisms  have  been  described  by  328 
which  antibodies  can  interfere  with  parasite  growth.  They  largely  depend  on  the  329 
antibody specificity. Antibodies directed against surface proteins of merozoites were  330 
shown  to  agglutinate merozoites  and  thereby  inhibit merozoite  dispersal  [53–55].  331 
Other  antibodies were  shown  to  prevent  antigen  processing  or  binding  to  surface  332 
ligands  required  for  the  merozoite  invasion  process  [56–58].  Furthermore,  333 
antibodies  can  mediate  clearance  of  free  merozoites  by  opsonization,  leading  to  334 
enhanced phagocytosis of merozoites or to complement‐mediated damage [59–61].  335 
Cytophilic  antibodies  bound  to  merozoite  surface  proteins  were  shown  to  induce  336 
destruction  of  merozoites  by  neutrophilic  respiratory  burst  [62]  or  inhibition  of  337 











pathology  [74,75].  Although  all  of  these  mechanisms  have  been  described,  their  346 
relative  contribution  to  naturally  acquired  protection  is  not  fully  understood.  347 
Important  to  note  is  that  not  all  malaria‐specific  antibodies  are  protective.  348 
Depending  on  the  specificity,  antibodies may  even  enhance  invasion,  prevent  the  349 
binding of inhibitory antibodies, or have no effect at all [76,77].  350 
Variant‐specific immunity  351 
A  special  role  for  acquired  immunity  has  been  ascribed  to  antibody  responses  to  352 
PfEMP1  and  other  variant  surface  antigens  (VSA)  expressed  at  knob‐structures  on  353 
the  membrane  of  infected  erythrocytes  [78].  PfEMP1  mediates  the  adhesion  of  354 
infected  erythrocytes  to  a  range  of  receptors  in  the  host  vasculature  and  thereby  355 
prevents clearance of infected cells in the spleen [79,80]. The P. falciparum genome  356 
contains approximately 60 var genes, each encoding a distinct PfEMP1 variant with  357 
particular  antigenic  and  adhesive  properties  [81].  Individual  infected  erythrocytes  358 
only express a  single variant at a  time, but are capable of  switching  the expressed  359 
variant  [82–84].  Antibody‐mediated  agglutination  experiments  could  show  that  360 
parasites  causing  clinical  disease  express  VSA  to  which  the  patient  has  no  pre‐ 361 
existing antibodies [85–88]. In response to disease, a VSA‐specific antibody response  362 
is  triggered,  but  offers  no  protection  to  other  variants  [85–88].  Hence,  sequential  363 
parasite  waves  observed  in  malaria  patients  are  understood  as  changes  in  the  364 
expression  of  variant  antigens.  Variant‐specific  antibodies  are  induced  and  control  365 
the  infection but expression  then switches  to a different variant not  recognized by  366 
the  pre‐existing  antibodies  [89].  Different  VSA mediate  adhesion  to  different  host  367 
receptors with different efficiency. VSAs mediating  sequestration  to certain  tissues  368 










thus  assumed  to  be  the  cumulative  product  of  exposure  to  multiple  parasite  376 
infections over  time. However,  data  from  transmigrant  studies  showed  that  adults  377 
acquire  immunity  more  rapidly  than  children  [93,94].  Within  a  two‐year  period  378 
migrants  acquired  protection  comparable  to  age‐matched  life‐long  residents.  This  379 
may  indicate  that  age  as  an  intrinsic  factor  independent  from  exposure,  may  380 
determine development of protective immunity [95].  381 
Malaria vaccine development  382 











vaccine  needs  to  induce  the  same  kind  of  immune  responses  responsible  for  394 
naturally  acquired  protection  but  just more  rapidly  and more  long‐lasting,  or  ii)  a  395 
vaccine  needs  to  evoke  a  type  of  immune  response  that  would  not  normally  be  396 
induced upon natural  infection but  is potent  in preventing  infection or disease. For  397 











As  described  above,  protective  immunity  to  the  pre‐erythrocytic  stages  is  not  406 
acquired by natural exposure [24]. However, sterile immunity to the pre‐erythrocytic  407 
stage  can  be  induced  experimentally.  Repeated  infection  with  attenuated  408 
sporozoites renders humans completely resistant to challenge  infections [100]. The  409 
protection was associated with effector memory T cell responses [101]. Additionally,  410 
although  naturally  acquired  antibodies  specific  for  sporozoites  do  not  confer  411 
protection from re‐infection [102], antibodies specific for sporozoite surface proteins  412 
have  been  described  to  block  invasion  of  hepatocytes  in  vitro  [103,104].  Thus,  a  413 
vaccine would have to target the pre‐erythorcytic stages either by inducing antibody  414 
responses that block  invasion of sporozoites  into hepatocytes or effector CD4+ and  415 
CD8+ T cells that interfere with development of liver stages. A vaccine that efficiently  416 
targets  pre‐erythrocytic  stages  may  be  capable  of  inducing  sterile  immunity  and  417 
would  consequently  prevent  morbidity  and  mortality  associated  with  blood  stage  418 
infection as well as transmission.  419 
The  most  prominent  pre‐erythrocytic  malaria  vaccine  antigen  is  CSP,  the  420 
predominant  surface  protein  of  sporozoites  [105].  The  most  advanced  malaria  421 
vaccine, RTS,S, consists of the hepatitis B surface antigen fused to the central repeat  422 
and  thrombospondin  domain  of  CSP  formulated  in  different  AS  adjuvants  [106].  423 
Approximately 30‐50% of children and infants immunized with RTS,S in clinical phase  424 
II  trials  conducted  in  endemic  countries  were  protected  from  clinical  malaria  425 
[97,107–110]. This vaccine is currently undergoing a phase III trial at 11 sites in seven  426 
countries  in  Africa,  involving  over  15’000  children  (www.clinicaltrials.gov  427 
(NCT00866619)).  Another  pre‐erythrocytic  vaccine  candidate  antigen  is  TRAP  428 
(thrombospondin  related  adhesive  protein)  found  in  the  micronemes  and  on  the  429 
surface  of  sporozoites.  It  has  been  implicated  in  gliding  motility  and  hepatocyte  430 




through  TRAP‐specific  IFN‐γ  producing  T  cells,  but  failed  to  induce  protection  in  432 
children  in  Africa  [113,114].  Also,  utilization  of  whole  sporozoites  as  a  vaccine  is  433 
currently  being  reconsidered.  Production  of  irradiation‐attenuated  sporozoite  434 
compliant  with  regulatory  requirements  for  clinical  use  was  achieved  [115],  but  435 






mainly  blood  stage  specific.  Blood  stage  vaccine  candidate  antigens  comprise  442 
proteins  expressed  on  the  surface  of merozoites,  like merozoite  surface  protein  1  443 
(MSP1)  [116],  MSP2  [117],  MSP3  [118–120]  and  glutamate‐rich  protein  (GLURP)  444 
[121,122],  or  proteins  released  from  secretory  organelles  upon  invasion,  like  445 
membrane antigen 1  (AMA1)  [123]  and erythrocyte‐binding antigen‐175  (EBA‐175)  446 
[124]. Naturally acquired immune responses to all these proteins have been variably  447 




dependent  on  monocytes  and  affects  parasite  replication  [118,121,131].  Vaccines  452 
based on all these antigens, except MSP2, were reported to induce protection from  453 
subsequent  challenge  in monkeys  [132–136].  Parasite  proteins  transported  to  the  454 
surface  of  infected  erythrocytes,  like  PfEMP1,  are  well‐described  targets  of  455 
protective  immune  responses  [137].  But  due  to  their  high  degree  of  antigenic  456 
diversity and their capacity for clonal antigenic variation, development of PfEMP1 as  457 
vaccine  is  a  challenging  task.  The  identification  of  conserved  epitopes  capable  of  458 
inducing antibodies preventing sequestration of a wide range of variants may pave  459 
the  way  for  a  PfEMP1‐based  vaccine  [138,139].  Furthermore,  certain  PfEMP1  460 
variants  are  associated  with  specific  clinical  presentations  [90–92].  For  example,  461 




pregnancy associated malaria vaccine  [140]. Var2csa  is expressed by P.  falciparum‐ 463 
infected  erythrocytes  and  mediates  adhesion  to  the  placental  lining  during  464 
pregnancy and is responsible for pregnancy‐associated malaria that can result in the  465 
mother’s  death,  low  birth weight  of  the  infant,  or  death  of  the  fetus  or  newborn  466 
[12,91].  467 
Only a handful of blood‐stage vaccines have been tested in phase II efficacy trials in  468 
humans.  “Combination  B”  vaccine,  based  on  recombinant MSP1,  MSP2  and  RESA  469 
(ring‐infected  erythrocyte  surface  antigen)  with  montanide  ISA720,  offered  no  470 
protection  to  blood  stage  challenge  in  malaria  naïve  adults  [141].  However,  this  471 
vaccine  reduced  parasite  density  and  reduced  infection  rates  with  MSP2  allelic  472 
variant included in the vaccine but not with the alternate allelic variant [96]. MSP1‐ 473 
42 in AS02A elicited high antigen‐specific antibody concentrations but no protection  474 





induced  growth‐inhibitory  activity  and  AMA1  antibody  titres  in  the  vaccine  group  480 
was observed [144]. The vaccine FMP2.1, based on recombinant AMA1 administered  481 
in  adjuvant  system  AS01B  or  AS02A,  showed  no  protective  effect  in  sporozoite  482 
challenge  experiments  in  naïve  adults,  but  data  suggest  reduced  parasite  growth  483 
rates  [145].  Recently,  it  was  reported  that  virosome  formulated  malaria  484 
peptidomimetics derived  from AMA‐1 and CSP  reduced  the  rate of  clinical malaria  485 





responsible  for  disease.  One  target  of  this  category  is  glycosylphosphatidylinositol  491 
(GPI), a component of the parasite membrane, which  is reported to have toxin‐like  492 








ingested  as  part  of  the  blood meal, would  target  antigens  on  gametes,  zygotes  or  498 
ookinetes and prevent parasite development  in  the mosquito midgut  [148]. Such a  499 
vaccine would confer no protection  to  the vaccinated  individual unless used  in  the  500 
entire  population  and  thereby  reducing  transmission  rates.  Transmission‐blocking  501 
vaccines  are  regarded  as  an  important  tool  for  the  recently  revived  ambition  for  502 
malaria  elimination  [149].  The  basic  concept  of  transmission‐blocking  vaccines  503 
derives  from experimental data  showing  that naturally  acquired as well  as  vaccine  504 
induced antibodies specific for surface proteins of sexual stages block development  505 
of mosquito stages [150–152]. These antibodies block parasite maturation either by  506 
interfering  with  fertilization  or  by  inducing  antibody‐dependent  complement  lysis  507 
[152,153].  Sexual  stage  antigens  considered  for  transmission‐blocking  vaccines  508 
include  Pfs25,  Pfs48/45,  and  Pfs230.  Antisera  of  mice  immunized  with  all  these  509 
antigens  conferred  high  reduction  in  the  average  oocyst  numbers  per  feeding  510 
mosquito [154–157].  511 
Transmission‐blocking  as  well  as  pre‐erythrocytic  vaccines  are  in  dispute  as  they  512 
reduce  exposure  to  blood  stage  parasites  and  consequently  naturally  acquired  513 
clinical immunity might be lost or its onset might be delayed in time. Depending on  514 














able  to  induce  some  protective  efficacy  so  far.  Since  the  fully  annotated  P.  525 
falciparum genome has become available in 2002, systematic screening of the more  526 
than  5000  hypothetical  proteins  represents  a  new  opportunity  to  identify  novel  527 
malaria  vaccine  candidates.  The  use  of  rational  selection  criteria  and  comparative  528 
analysis  of  vaccine  candidates  will  aid  in  the  development  of  a  highly  effective  529 
malaria vaccine.  530 
In  this  thesis, we anticipate the rational discovery of novel malaria subunit vaccine  531 
candidates. Our strategy is based on the selection of hypothetical parasite proteins  532 
that are accessible to the host immune surveillance and their subsequent functional  533 
characterization  using  specific  monoclonal  antibodies.  This  includes  three  main  534 
elements:  535 
1. Identification  of  candidate  hypothetical  proteins  based  on  the  predicted  536 
protein localization, expression pattern, homologies and domain predictions.  537 
2. Assessment  of  expression,  localization,  processing  and  protein  function  of  538 
selected candidates and determination of their potential as molecular target  539 
for  a malaria  subunit  vaccine by  functional  assays with  specific monoclonal  540 
antibodies.  541 
3. Generation of  antibodies  capable of  recognizing  the endogenous antigen  in  542 
its native context is considered crucial for their use in functional  in vitro and  543 
in vivo assays; therefore we aimed at developing a novel protein expression  544 

























































































The  generation  of  monoclonal  antibodies  specific  for  protein  antigens  usually 
depends  on  purified  recombinant  protein  for  both  immunisation  and  hybridoma 
screening.  Purification  of  recombinant  protein  in  sufficient  yield  and  purity  is  a 




We  describe  a  strategy  to  generate  monoclonal  antibodies  against  membrane  or 
membrane‐associated  proteins  that  completely  bypasses  any  need  for  purified 
recombinant  antigen.  This  approach  utilises  stably  transfected  mammalian  cells 
expressing recombinant antigens on their cell surface for immunisation of mice. The 







The  described  entirely  cell‐based  technology  is  a  fast  and  efficient  approach  for 






Since  the  development  of  the  B‐cell  hybridoma  technology  for  the  generation  of 
monoclonal  antibodies  (mAbs)  in  1975  by  Kohler  and  Milstein  [1],  mAbs  have 
become molecular tools of great value. Due to their high specificity, mAbs are used 
throughout  biology  for  the  characterisation  of  protein  function  and  distribution. 
Besides  their  usage  in  research,  mAbs  are  also  widely  utilised  as  diagnostic  and 
therapeutic agents  [2][3]. Due  to  this wide  range of applications  the generation of 
mAbs  became  a  standard  procedure.  However  the  generation  of  mAbs  against 
protein antigens can still be problematic, since for studies in physiological settings, it 
is important that the mAbs recognise the target protein in its native conformation. 
Frequently, mAbs are  raised against  synthetic peptides derived  from  the predicted 
sequence of  the  target protein. Unfortunately,  these Abs,  though  strongly  reactive 
with  peptide,  frequently  fail  to  recognise  the  native  protein  [4].  Another  standard 
procedure  to  generate  mAbs  uses  purified  recombinantly  expressed  proteins. 
Prokaryotic expression systems are the most widely used expression hosts. But when 
studying  mammalian  surface  proteins  it  is  often  necessary  to  use  mammalian 
expression systems, as they are more likely to produce functional proteins with the 
appropriate  disulfide‐bonds  and  posttranslational  modifications  [5][6].  Although 
introduction of affinity tags simplifies purification, it often remains difficult to obtain 
recombinant protein  in native  conformation and  in  sufficient  yield and purity.  This 
applies most notably to membrane and membrane‐associated proteins, as they are 
likely to lose their native structure during the purification processes [7]. 
When attempting to generate mAbs capable of  recognising the native protein,  it  is 
also  critical  to  use  the  target  protein  in  its  native  conformation  not  only  in  the 
immunisation step but also for the screening procedure. Many standard hybridoma‐







need  for purified  recombinant protein. This  strategy utilises antigens expressed on 
the surface of stably transfected mammalian cells both for immunisation of mice and 
for  immunoassays,  such  as  testing  seroconversion,  hybridoma  selection  and  mAb 
characterisation. 
In  the  present  study,  we  applied  this  approach  for  three  predicted  GPI‐anchored 
proteins of Plasmodium falciparum. P.  falciparum  is  the causative agent of malaria 
tropica, which claims 300‐600 million clinical cases and more than 2 million deaths 
each  year  [9]. Malaria  is  transmitted  to  humans  by  the  bite  of  an  infected  female 
Anopheles  mosquito.  The  inoculated  sporozoites  infect  hepatocytes  where  the 
parasites undergo  schizogony  resulting  in  the  rupture of  the  infected  liver  cell  and 
release  of  free  merozoites,  which  infect  erythrocytes.  Upon  intra‐erythrocytic 
schizogony  red  blood  cells  rupture  and  release  more  merozoites.  Some  of  these 
differentiate  into gametocytes, which, when  taken up by a  feeding mosquito bring 
about  the  sexual  cycle,  resulting  in  the  development  of  sporozoites  located  in  the 
salivary  gland  of  the  mosquito.  Highly  specific  cell‐cell  interactions  between  the 
invasive  forms of  the parasite and the corresponding host cells are pivotal steps  in 
the  complex  life  cycle  of  P.  falciparum,  which  depend  on  specific  molecular 
interactions  of  cell  surface  molecules.  Being  exposed  to  potentially  parasite 





tool  to  characterize  their  properties  and  potential  as  vaccine  candidate  antigens. 
Based on being predicted  to be expressed  in  invasive  stages and  to  contain a GPI‐
anchor motif,  three hypothetical proteins were selected: PFF0620c, PFD1130w and 
PF14_0325.  For  PFD1130w  and  PF14_0325  published  transcriptional  analysis  data 
showed  elevated  expression  levels  in  late  stages  of  the  asexual  blood  stage  cycle 
[11][12].  For  both  predicted  proteins  no  function  can  currently  be  assigned  as  no 





which  are  characterized  by  the  presence  of  6  cysteines.  Other  members  of  this 
protein  family  have  been  shown  to  be  located  on  the  surface  of  the  parasite  and 
some  of  them  are  known  to  play  a  role  in  cell‐cell  interactions  [13].  Mass 
spectrometry data indicate expression of PFF0620c at the sporozoite stage [14]. 
To  achieve  surface  localisation  of  the  recombinant  P.  falciparum  proteins  on 
mammalian cells despite potential differences of  the secretory machinery between 
Plasmodium  and  host  cells,  the  P.  falciparum  coding  sequences  were  altered  in 
several ways. The endogenous secretion signal sequences and GPI‐attachment sites 
were  replaced  with  the  signal  peptide  of  bee  venom  melittin  and  the 
transmembrane domain of mouse glycophorine A, respectively. To allow assessment 
of  surface  localization,  antibody‐tags  were  introduced  on  both  sides  of  the 
transmembrane domain. 
We expect that this entirely cell‐based system, capable of generating mAbs against 






Expression  of  predicted  GPI‐anchored  P.  falciparum  proteins  on  the  cell 
surface of mammalian cells 




pcDNA3.1_BVM_PF14_0325_FLAG_GLP_His,  respectively  (Figure  1).  To  ensure 
expression on the cell surface, the predicted ORFs were modified in several ways: i. 
the  endogenous  P.  falciparum  sequences  were  codon‐optimised  for  expression  in 
mammalian  cells;  ii.  the  endogenous  secretion  signal  sequences were  replaced  by 
the  secretion  signal  sequence  of  bee‐venom melittin;  iii.  for membrane  anchoring 
the  transmembrane  domain  encoding  sequence  of  mouse  glycophorin  was  used 
instead  of  the  predicted  GPI‐attachment  signal  sequences;  iv.  to  allow  expression 
analysis, a FLAG tag was inserted N‐terminally of the transmembrane domain and a 
hexa‐His tag was placed at the C‐terminus. The two tags were positioned just before 




were  established  by  stable  transfection.  Expression  of  recombinant  proteins  was 
confirmed by Western blot analysis using anti‐His tag and anti‐FLAG tag antibodies. 
While protein bands appeared when lysates of the three stably transfected cell lines 
were  analysed,  no  staining was  obtained with  non‐transfected HEK  cells  (data  not 








pcDNA3.1  BVM_PFD1130W_FLAG_GP_His  and  pcDNA3.1  BVM_PF14_0325_FLAG_GP_His  (pcDNA3.1  BVM_P. 








or  PF14_0325.  The  hypothetical  P.  falciparum  proteins  PFF0620C,  PFD1130W  or  PF14_0325  (left),  and  their 






To  obtain  highly  expressing  cell  lines,  transfectants  were  separated  into  high‐
expressing cell‐pools by fluorescent‐activated‐cell‐sorting after surface staining with 
anti‐FLAG  tag  antibodies.  After  several  days  in  culture  the  mean  fluorescence 
intensities  of  the  high‐expressing  cell  pools  of  the  transfectants  PFF0620c‐HEK, 








Figure  3.  Detection  of  the  P.  falciparum  proteins  PFF0620C,  PFD1130W  or  PF14_0325  displayed  on  stably 
transfected HEK cells. Histogram plots show flow‐cytometric analysis of non‐transfected and high‐expressing cell 
pools  of  transfected  HEK  cells  (PFF0620C‐HEK,  PFD1130W‐HEK,  PF14_0325‐HEK)  stained  with  anti‐His  tag 
antibody (A) or anti‐FLAG tag antibody (B). 
 
Live‐cell  staining  of  PFF0620c‐HEK,  PFD1130W‐HEK  or  PF14_0325‐HEK  cells  with 
anti‐FLAG tag antibody yielded strong signals.  In contrast, staining with anti‐His tag 
antibody gave strong signals on methanol fixed cells but not on living cells (Figure 4). 
From  these  results  we  deduced  that  PFF0620c,  PFD1130W  and  PF14_0325  were 










Figure  4.  Cell‐surface  expression  of  PFF0620C,  PFD1130W  or  PF14_0325  on  stably  transfected  HEK  cells. 









The  high‐expressing  cell  pools  PFF0620c‐HEK,  PFD1130W‐HEK  and  PF14_0325‐HEK 
were used to immunise NMRI mice. Mice received intravenous injections of 106 cells 
on  three  consecutive  days  and  another  suite  of  three  daily  injections  two  weeks 
later.  Development  of  serum  antibody  titres  was  analysed  by  flow  cytometry 
comparing  immune‐staining  of  the  corresponding  transfectants  with  that  of  non‐
transfected  HEK  cells  (Figure  5).  The  fluorescence  intensity  observed  with 
transfectants was two‐ to four‐fold higher than that of non‐transfected control HEK 





Figure  5.  Staining  of  transfected HEK  cells  by  serum  antibodies  of  immunised mice. The  graph  shows mean 
fluorescence intensities (MFI) obtained by flow‐cytometric analysis of transfected and non‐transfected HEK cells 




myeloma cells  to generate B  cell hybridomas.  Fused cells were distributed  in 1152 
microtitre  culture  plate  wells.  To  identify  hybridoma  cells  that  produce  malaria 
antigen specific antibodies a two‐step screening procedure was used that completely 
obviated  the  requirement  for  purified  recombinant  proteins.  First  all  culture wells 
were  tested  for  IgG production by ELISA. Between 18 and 29% of  the  tested wells 
were  IgG  positive  (Table  1).  In  a  second  step  all  wells  positive  for  IgG  production 
were  screened  by  IFA  for  antibodies  binding  to  transfected  cells.  Transfected  and 
non‐transfected  HEK  cells  spotted  onto  multiwell  glass  slides  were  stained  with 
individual hybridoma supernatants and analysed by fluorescence microscopy (Figure 




untransfected  HEK  cells.  Among  these,  eight  wells  were  identified  that  contained 





the  membrane  anchor  domain.  All  other  culture  supernatants  reactive  with 
transfectants, but not with untransfected HEK cells were specific for the transfected 
cells used for immunisation and did not stain the two other transfectants (Table 1). 
From  wells  of  this  category,  17,  nine  and  two  hybridoma  clones  (Table  2)  were 




 IgG ELISA screena  IFA screen on transfected and non-transfected HEK cellsb  
Antigen 






PFF0620c   1152 335 29%   142 42%   86 60%   25 18%   30 21%   1 0.7% 
PFD1130w   1152 294 26%   294 100%   200 68%   10 3%   83 28%   1 0.3% 





















analysis  (Figure  7).  With  the  exception  of  one  anti‐PFF0620c  mAb,  all  28  mAbs 
stained the corresponding recombinant protein in the lysate of the transfectant used 
for  immunisation, but not  in  lysates of  the other  transfectants or of untransfected 
HEK cells  (Table 2).  Interestingly,  in Western blot analysis anti‐PFF0620c mAbs only 






Figure  6.  Immunofluorescence  microscopic  screening  of 
hybridoma cell culture supernatants for antibodies binding to 
cell‐surface  expressed  PFF0620C.  PFF0620C‐HEK  cells  (right 
column) and untransfected HEK  cells  (left  column) were  fixed 
with  methanol  and  stained  with  hybridoma  supernatants  of 
individual  cell  culture wells  taken  15  days  after  the  fusion.  A 
FITC‐labelled  anti‐mouse  IgG  antibody  served  as  secondary 
antibody.  Representative  fluorescence  micrographs  from  the 
PFF0620C‐fusion  are  shown,  demonstrating  typical  results  for 
hybidoma  lines  producing  PFF0620C‐specific  (line  1,  2  &  3), 
non‐binding  (line  4),  or HEK  cell  antigen  specific    (line  5 & 6) 
antibodies.  For  some  wells  mixed  specificity  was  seen, 
indicating  presence  of  two  ore  more  cell  clones  with  one 










Figure  7.  Western  blot  analysis  of  generated  monoclonal  antibodies  with  the  recombinant  P.  falciparum 







Reactivity  of  the  generated  monoclonal  antibodies  with  the  endogenous 
target antigens. 
To  determine whether  the  generated mAbs  selected  against  ectopically  expressed 
PFF0620c,  PFD1130W or  PF14_0325 would  bind  to  the  endogenous  proteins  of  P. 
falciparum parasites, we performed  IFA  and Western‐blot  analysis  using  cultivated 
blood‐stage  parasites  and mosquito  salivary  gland‐derived  sporozoites  (Figure  8 & 
Table  2).  All  nine  generated  anti‐PFD1130W  mAbs  recognised  a  discrete  band  of 
about  40  kDa,  corresponding  to  the predicted molecular weight  of  the PFD1130W 
protein. Furthermore all nine mAbs stained blood‐stage parasites in IFA, resulting in 
a distinctive staining pattern (Figure 8 & Table 2). Both anti‐PF14_0325 mAbs were 
Western‐blot  positive  on  blood  stage  parasite  lysate  and  stained  specifically  late 
blood  stage parasites  in  IFA  (Figure 8 & Table  2).  Thirteen of  the  seventeen mAbs 









Figure  8.  Reactivity  of  generated  monoclonal  antibodies  with  the  endogenous  P.  falciparum  proteins. 
Fluorescence staining (column 2, 3 & 4) and DIC micrographs (column 1) of P. falciparum parasites. While anti‐
PFF0620C  mAb  specifically  stained  salivary  gland  sporozoites  (line  5),  anti‐PF14_0325  mAb  (line  3)  and  anti‐











      Western blotting analysis   IFA 
 Hybridoma 
Clone 














PFF0620c 01 IgG2a   − + − −  − + − + 
PFF0620c 02 IgG2a   − + − −  − + − − 
PFF0620c 06 IgG1   − + − −  − + − + 
PFF0620c 07 IgG2a   − + − −  − + − + 
PFF0620c 08 IgG1   − + − −  − + − − 
PFF0620c 09 IgG1   − + − −  − + − + 
PFF0620c 10 IgG1   − + − −  − + − + 
PFF0620c 11 IgG1   − + − −  − + − + 
PFF0620c 13 IgG2a   − + − −  − + − + 
PFF0620c 17 IgG2b   − + − −  − + − + 
PFF0620c 19 IgG1   − + − −  − + − − 
PFF0620c 21 IgG2b   − + − −  − + − + 
PFF0620c 22 IgG1   − + − −  − + − + 
PFF0620c 25 IgG1   − + − −  − + − + 
PFF0620c 27 IgG2b   − + − −  − + − − 
PFF0620c 29 IgG1   − + − −  − + − + 
PFF0620c 32 IgG1   − − − −  − + − + 
      0/17 16/17 0/17 0/17  0/17 17/17 0/17 13/17 
               
 Hybridoma 
Clone 














PFD1130w 02 IgG2b   − + + −  − + + − 
PFD1130w 04 IgG3   − + + −  − + + − 
PFD1130w 05 IgG2a   − + + −  − + + − 
PFD1130w 06 IgG2a   − + + −  − + + − 
PFD1130w 08 IgG1   − + + −  − + + − 
PFD1130w 09 IgG3   − + + −  − + + − 
PFD1130w 10 IgG1   − + + −  − + + − 
PFD1130w 12 IgG2a   − + + −  − + + − 
PFD1130w 13 IgG1/ 
IgG2b 
  − + + −  − + + − 
      0/9 9/9 9/9 0/9  0/9 9/9 9/9 0/9 
               
 Hybridoma 
Clone 














PF14_0325 02 IgG1   − + + nd  − + + nd 
PF14_0325 04 IgG1   − + + nd  − + + nd 
      0/2 2/2 2/2   0/2 2/2 2/2  






of  the  cell  and  selectively mediate  the  flow of  information  and nutrients  between 
the outside and inside of the cell. Functions of membrane proteins include: transport 
of  substances  across  membranes,  enzymatic  activity,  signal  transduction, 
intercellular  joining,  cell‐cell  recognition,  attachment  to  the  cytoskeleton  and 
extracellular matrix.  Even  though only 25% of all  proteins are membrane proteins, 
about 60% of  today’s  approved drug  targets are membrane proteins  [15]. Also  for 
subunit  vaccine  design  cell  surface  associated  proteins,  which  can  be  accessed  by 
antibodies,  are  of  prime  interest.  Nonetheless  the  basic  knowledge  about  these 
proteins lags far behind that of soluble proteins. This is due to difficulties in ectopic 
expression, purification and protein  stability.  Therefore  investigation of membrane 
proteins  is  a  demanding  undertaking  and  generation  of  mAbs  against  membrane 
proteins represents a difficult task. 
Here we described a procedure to generate mAbs specific for cell‐surface associated 
proteins,  which  completely  bypasses  any  need  for  purified  antigen.  This  is  highly 
desirable  as  it  supersedes  the  laborious  task  of  antigen  purification  and  ensures 
presentation of target proteins in their native conformation. In a study using antigen 
expressing  transfectant  cells  to generate  single  chain antibodies  it was  shown  that 
cell‐based selection was far more efficient in generating Abs cross‐reactive with the 
native endogenous protein than selection with purified recombinant protein [16]. 
The  principal  steps  of  the  applied  procedure  are  the  following:  (I)  generation  of 
stably  transfected mammalian cells, expressing high  levels of  the target antigen on 
their  surface  in  a  native  conformation;  (II)  immunisation  of mice with  transfected 
cells; (III) hybridoma cell generation; (IV) selection of hybridoma cells by a two step 
screening  procedure  involving  an  anti‐IgG  ELISA  and  an  IFA  with  transfected  and 
non‐transfected cells. Only one single transfected cell  line is required for the whole 









tag was only  accessible upon  fixation with methanol  in  IFA, whereas  the  FLAG  tag 
was accessible on  live cells. From these results we deduced that all  three cell  lines 
presented  recombinant  protein  on  their  cell  surface.  Flow  cytometric  analysis 
showed  that  the  staining  intensity with  the  anti‐FLAG  tag  and  anti‐His  tag Ab was 
varying  between  the  three  different  transfectants.  The  finding  that  transfectants 
showing the lowest staining with the anti‐FLAG tag Ab showed the strongest staining 
with  the anti‐His  tag Ab could  indicate  that  the percentage of  correctly orientated 
protein  molecules  is  varying  between  the  different  transfectants.  However, 





In  order  to  generate  recombinant  proteins  with  natural  conformation,  it  is  most 
favourable to use expression hosts of the same biological kingdom, since they likely 
produce  the  same  post‐translational modifications  and  recognise  the  same  signals 
for  synthesis,  processing,  and  secretion  as  the  organism, which  the  sequence was 
originally derived from. As we were dealing with Plasmodium proteins, this objective 
could not be fulfilled, because currently no Apicomplexa‐based expression system is 
described.  Anticipating  surface  expression  and  natural  conformation,  the  protein 
encoding  sequence  was  genetically  modified  in  several  ways.  Firstly  codon‐usage 
was optimised  for mammalian  cells,  as  the plasmodium genome  is extremely A+T‐
rich.  The  overall  (A  +  T)  composition  is  80.6%,  and  rises  to  90%  in  introns  and 
intergenic  regions  [19].  Furthermore  the  endogenous  GPI‐attachment  signal 
sequence was replaced by a transmembrane alpha helix of mouse glycophorin‐A to 




in  the  GPI‐attachment  machinery  [20][21].  Whether  recombinantly  expressed 
proteins  will  contain  the  same  posttranslational  modifications  as  the  endogenous 
protein was uncertain. Plasmodium species have undergone a process of gene  loss 
that has removed much of their capacity to produce glycosylated proteins other than 
GPI‐anchored  proteins  [22].  Therefore  recombinant  expression  of  P.  falciparum 
proteins  in  mammalian  cells  takes  a  risk  of  generating  glycosylated  forms  of  the 
protein, which are not found in the parasite.  Generated mAbs might therefore not 
be capable of  recognising the unglycosylated endogenous protein. However,  in  the 
study presented here 24 out of 28 generated mAbs were capable of recognising the 
endogenous  protein  in  IFA.  Therefore  potential  differences  in  the  glycosylation 
status  of  recombinant  and  endogenous  protein  were  inconsequential  for  antigen‐
antibody  interactions.  Beside  protein  glycosylation,  disulfide  bonds  play  an 
important role in the folding and stability of proteins, especially for proteins secreted 
to the extracellular medium. PFF0620c is predicted to contain two s48/45 domains. 
These  domains  are  known  to  contain  six  position‐conserved  cysteine  residues, 
resulting  in  a  conserved  set  of  disulfide  bonds  [23][24].  Generated  anti‐PFF0620c 
mAbs only reacted with recombinant PFF0620c when analysed under non‐reducing 
conditions,  indicating  that  PFF0620c  expressed  in  HEK  cells  contained  disulfide 
bridges.  As  13  out  of  17  mAbs  recognised  endogenous  PFF0620c  in  IFA,  disulfide 
bridge  formation  in  HEK  cells  is  likely  to  have  resulted  in  endogenous  protein‐like 
structures. 
To our knowledge, the present study shows for the first time that antigen‐expressing 
tranfectants  of  xenogenic  origin  can  well  be  used  for  immunisation  of  mice  to 
efficiently  generate  antigen‐specific  mAbs.  In  the  described  procedure  we  used  a 
human derived cell  line (HEK) for  immunisation of mice. Usage of HEK cells has the 




immunised with  cells  of  xenogenic  origin  generate  an  excess  of  antibodies  against 





cells. However,  this  procedure  generated  also mAbs  against  the  target  antigens  at 
high frequencies (Table 1). On the other hand one could speculate that immunisation 
with xenogenic transfectants possibly results in a stronger activation of the immune 
system  than  immunisation  with  allogenic  cells.  Interestingly,  the  percentage  of 
transgene‐specific  clones  generated  in  the  three  individual  fusions  correlated with 
the malaria antigen expression level of the corresponding transfected cells used for 
the  immunisation  of mice.  This  indicates  that  high  expression  levels  of  the  target 
antigen  are  needed.    It  remains  to  be  elucidated  in  more  detail  how  expression 
strength  and  cell  line  origin  affect  the  efficiency  of  mAb  generation  by  this 
procedure. Anyhow, our  results  indicate  that any kind of cell  line, which expresses 
the  antigen  in  decent  amounts,  can  be  used  for  the  generation  of  mAbs  by  the 
described procedure. 
The  two‐step  screening  procedure  consisting  of  an  IgG‐ELISA  followed  by  IFA  of 
transfected cells was quick, and the readout straightforward. In other studies using 
antigen‐expressing  cells  for  immunisation  and  hybridoma  selection,  either 
hybridoma  supernatants  have  been  analysed  by  flow  cytometry  or  a  reporter  cell 
line has been used [16][26]. These screening strategies represent alternatives to the 
two‐step  screening procedure described here. This would have  the advantage  that 
hybridoma  supernatants  are  screened  for  reactivity  to  living  transfectants  and not 
against  cells  that  had  undergone  a  fixation  processes.  However,  both  for  flow 
cytometric  and  for  reporter  cell  analysis,  antigen‐expressing  cells  need  to  be 
available  in  appropriate  quality  and  number  over  the  extended  and  not  entirely 
predictable  time  period  when  hybridomas  are  ready  for  primary  and  secondary 
screening.  In  contrast,  the  described  IFA‐screen  can  be  performed  with  slides 
prepared prior to the fusion and stored at ‐80°C.  
Conclusions 
These  results  demonstrate  that  our  cell‐based  system  of  immunisation  and 












A double‐stranded oligonucleotide  encoding  the  secretion  signal  sequence  of  bee‐
venom  melittin  was  ligated  to  NheI  digested  pcDNA3.1  (Invitrogen)  resulting  in 
plasmid  pcDNA3.1_BVM.  Mouse  glycophorin‐A  mRNA  was  obtained  from  mouse 
bone marrow cells and cDNA generated by two‐step reverse‐transcription PCR using 
primers designed  to amplify  specifically  the  cDNA of  the  transmembrane encoding 
region  of  glycophorin‐A.  This  sequence  was  then  ligated  to  NotI  digested 
pcDNA3.1_BVM  resulting  in  plasmid  pcDNA3.1_BVM_GP_His.  The  plasmid  was 
constructed  such  that  unique  NheI  and  NotI  sites  were  preserved  in  the multiple 
cloning  site.  Then  plasmid  pUC57  containing  codon  optimised  synthetic  genes 
encoding P. falciparum genes PF14_0325, PFD1130W or PFF0620C respectively that 
lack  sequences  for  the  secretion  signal  peptide  and  for  the  GPI‐attachment  signal 
peptide  (Genscript), were  ligated  into NotI/NheI  digested  pcDNA3.1_BVM_GP_His. 
Thereafter a double‐stranded oligonucleotide encoding a FLAG tag was  ligated  into 
the  NotI  site  resulting  in  expression  plasmids  pcDNA3.1_BVM_PF14_0325‐ 
_FLAG_GP_His,  pcDNA3.1_BVM_PFD1130W_FLAG_GP_His  and  pcDNA3.1_BVM_‐ 
PFF0620C_FLAG_GP_His. 
Culture of eukaryotic cells 
The  human  embryonic  kidney  cell  line  293  HEK  was  obtained  from  the  American 












Transfection  was  performed  following  the  manufacturer’s  protocol.  3  μg  of 
expression plasmid and 6 μl transfection solution was used. Antibiotic selection was 
started  48  h  after  transfection.  The  selection  medium  containing  500  ug/ml  of 
Geneticin (Gibco) was exchanged every 3‐4 days.  
Generation of anti‐FLAG tag and anti‐His tag mAb 
The  mAbs  His‐6/9  and  FLAG‐27  were  raised  in  Naval  Medical  Research  Institute 
(NMRI)  mice  injected  intraperitoneally  with  20  µg  of  the  respective  peptides 
CGGHHHHH  and  CGGDYKDDDDL  conjugated  to  KLH  (Imject®  Maleimide  Activated 
mcKLH, Pierce) and emulsified in aluminum hydroxide gel (Alhydrogel‐2%, Brenntag 
Biosector)  containing  CPG‐OGN  according  to  Davis  et  al  1998  [27].    The  animals 
received  up  to  four  booster  injections  each  at  3‐week  intervals  with  the  same 
antigen preparation. As soon as the animals showed a specific immune response to 




HEK  cells  were  collected  using  enzyme  free  dissociation  buffer  (Cell  dissociation 
buffer enzyme‐free Hanks’‐based, Gibco), washed with PBS and spotted on multiwall 
glass  slides  (multitest  slide,  12‐well,  7mm,  ICN  Biomedicals  Inc.).  When  air‐dried, 








were  added  to  the  wells  and  incubated  for  20  min  in  a  humid  chamber  at  37°C. 
Finally,  slides  were  rinsed  twice  and  washed  for  15  min  in  PBS,  mounted  with 
mounting  solution  (50%  PBS  50%  glycerol)  and  covered with  a  coverslip.  Stainings 
were  assessed  by  fluorescence  microscopy  on  a  Leica  CTR500  fluorescence 
microscope and a Leica DFC300 FX digital camera. 
Immunofluorescence staining of living HEK cells 
For  immunofluorescence staining of  live HEK cells chamber slides  (4‐well  chamber‐
slide, Lab‐Tek™, NuncTM) were used. Wells were coated with 100mg/l poly‐D‐lysine 
in  H2O  in  a  humid  box  at  room  temperature  over  night.  After  washing  the  wells 
three times with sterile H2O, 40’000 cells were seeded per well. Three days later the 
immunostaining  was  performed  by  incubating  the  wells  with  500  μl  of  an 
appropriate  mAb  diluted  in  serum‐free  culture  medium  for  30  min  on  ice.  After 
washing  two  times  with  serum‐free  culture  medium  500  μl  of  100  μg/ml  FITC‐
conjugated  goat  anti‐mouse  IgG  antibodies  (RAM/IgG(H+L)/FITC,  Nordic 
Immunological  Laboratories)  diluted  in  serum‐free  culture medium were  added  to 
the wells and incubated for 30 min on ice. Finally, the wells were rinsed twice with 





HEK  cells  were  collected  using  enzyme  free  dissociation  buffer  (Cell  dissociation 
buffer  enzyme‐free  Hanks’‐based,  Gibco),  and  washed  two  times  with  PBS.  To 
prepare  cell  lysate,  106  cells were  lysed with  0.1ml  of  lysis  buffer  (1% NP40,  10% 
glycerol, 2mM EDTA, 137mM NaCl, 20mM TrisHCl, pH8, Protease  Inhibitors)  for 10 
min on ice. The lysate was cleared by centrifugation at 20’000 g for 5 min. 
Blood  stage  parasite  lysates  were  prepared  essentially  as  described  previously  by 






20 min.  Finally,  the  pelleted  parasites were  resuspended  in  3  volumes  of  PBS  and 
stored at −80 °C until further use. 
For  SDS‐PAGE  cell‐  or  parasite  lysate was  resolved  on  precast  4‐12%  gradient  gels 
(NuPAGE® Novex 4‐12% Bis‐Tris Gel,  Invitrogen) with MES running buffer according 
to  the manufacturer’s directions. The proteins were electrophoretically  transferred 




blocking  buffer  and  incubated with  horseradish  peroxidase  conjugated  anti‐mouse 
IgG  mAb  (GAM/IgG  (γ‐chain)/HRP)  diluted  1:10’000  in  blocking  buffer  at  room 
temperature for 1 h. After washing again, blots were developed using ECL Western 
blotting  detection  reagents  (ECL  Western  Blotting  Substrate,  Pierce)  to  visualise 
bands. 
FACS and Flow cytometric analysis of HEK cells 
For  sorting  stably  transfected  cells  into  high‐expressing  cell  pools,  cells  were 
dissociated  with  enzyme‐free  dissociation  buffer  (Cell  dissociation  buffer  enzyme‐
free Hanks’‐based, Gibco), washed with blocking buffer (PBS containing 3% BSA). The 
cells were then incubated with 200 μl of 100 μg/ml FLAG‐27 mAb diluted in blocking 
buffer  for  15  min  on  ice.  The  cells  were  then  washed  with  blocking  buffer  and 
incubated with 200 μl of 100 μg/ml FITC‐conjugated goat anti‐mouse IgG antibodies 
(RAM/IgG(H+L)/FITC, Nordic  Immunological  Laboratories) diluted  in blocking buffer 
for 15 min on ice. After a final wash the labelled cells were analysed and sorted using 
a  Becton  Dickinson  FACSAria  running  Diva  software.  All  analyses  were  performed 
using  appropriate  scatter  gates  to  exclude  cellular  debris  and  aggregates.  Gating 
settings were set to collect highly labelled cells. Post‐sorting, the cells were collected 
in culture medium with 20% FCS and plated in 35 mm wells 
For  monitoring  surface  expression  of  PF14_0325,  PFD1130W  or  PFF0620C  on 
transfected  cell  lines,  cells  were  stained  as  described  above.  FACS  analysis  was 





cells  served  as  negative  control.  For  analysing  seroconversion  of  immunised mice, 









to  three weeks after  the boost, blood was collected and  the serum was  tested  for 






were  sacrificed  and  the  spleen  was  removed.  Spleen  cells  were  harvested  by 
trituration  under  sterile  conditions  and  fused  with  the  myeloma  cell  partner  (PAI 
















times,  plates  were  incubated  with  50  μl  horseradish  peroxidase‐conjugated  goat 
anti‐mouse IgG (γ‐chain specific) (Sigma) diluted 1:1000 in blocking buffer for 1 h at 
room‐temperature  in  a  humid  box  in  the  dark.  After  washing  4  times,  TMB 
peroxidase substrate solution was added and the colour change monitored. 
Antibody production and characterisation 





P.  falciparum  strain  3d7 was  cultured  essentially  as  described  previously  [29].  The 
culture medium was  supplemented with 0.5% AlbuMAX  (Gibco) as a  substitute  for 
human  serum  [30].  Cultures  were  synchronised  by  sorbitol  treatment  [31]. 
Erythrocytes for passages were obtained from the Swiss Red Cross (Switzerland). 
Immunofluorescence staining of P. falciparum 
Erythrocytes  from  in  vitro  cultures  of  P.  falciparum  strain  3d7  were  fixed  in 
paraformaldehyde‐glutaraldehyde as described previously [3]. Cells were blocked by 
incubation  in 3% BSA  in PBS  for 1h.  Immunostaining was performed by  incubation 
with  an  appropriate mAb  dilution  in  blocking  solution  for  1  h.  After  three washes 
with PBS, 5 μg/ml cyanine dye (Cy3)‐conjugated affinity‐pure F(ab′)2 fragment goat 
anti‐mouse  IgG  (Fc‐specific)  antibodies  (Jackson  Immuno  Research  Laboratories) 
diluted in blocking solution was added and incubated for 1 h at RT. Finally cells were 
washed  three  times  with  PBS,  mounted  with  mounting  medium  containing  DAPI 
(ProLong® Gold antifade reagent with DAPI, Invitrogen) and covered with a coverslip. 
Antibody stainings were assessed as described above. 
For  immunfluorescence  staining  of  sporozoites,  air‐dried  unfixed  P.  falciparum 












phenylindole;  DIC:  differential  interference  contrast;  ELISA:  Enzyme‐linked 
Immunosorbent  Assay;  FACS:  Fluorescence  activated  cell  sorting;  FCS:  foetal  calf 
serum;  GPI:  Glycosylphosphatidylinositol;  HAT:  Hypoxanthine  Aminopterin 
Thymidine;  HEK:  Human  Embryonic  kidney  cells;  IFA:  Immuno‐fluorescence  Assay; 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Figure  S1.  DNA  and  amino  acid  sequence  of  the  antigen  modifications.  Protein‐coding 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that of  proteins  known  to be  involved  in merozoite  invasion.  Immunofluorescence  25 
staining  localised  CyRPA  at  the  apex  of  merozoites.  The  entire  protein  is  highly  26 
conserved as shown by sequencing of the CyRPA encoding gene from a diverse range  27 
of  P.  falciparum  isolates.  CyRPA‐specific  monoclonal  antibodies  substantially  28 
inhibited parasite growth in vitro as well as in a P. falciparum animal model based on  29 
NOD‐scid  IL2Rγnull mice engrafted with human erythrocytes.  In  contrast  to other P.  30 
falciparum  mouse  models  this  system  generated  very  consistent  results  and  31 
therefore represents an unprecedented in vivo model for quantitative comparison of  32 
the  functional potencies of malaria  specific antibodies. Our data  suggest a  role  for  33 
CyRPA in erythrocyte invasion by the merozoite. Inhibition of merozoite invasion by  34 







Albeit  being  preventable  and  curable,  malaria  was  estimated  to  have  claimed  38 
781’000 deaths  in 2009  [1]. Besides other control measures,  implementation of an  39 
effective vaccine against malaria  is  regarded as a cost‐effective measure  to  reduce  40 
mortality  and  morbidity.  Three  different  malaria  vaccine  strategies  can  be  41 
distinguished:  infection‐blocking  vaccines  targeting  pre‐erythrocytic  stages,  anti‐ 42 
morbidity  vaccines  targeting  the  erythrocytic  stages  and  transmission‐blocking  43 
vaccines  targeting  the  sexual  stages.  It  is  assumed  that  a  highly  effective  malaria  44 
vaccine needs to be targeting multiple stages of the parasite life cycle [2,3].  45 
Importance  of  a  parasite  blood‐stage  component  in  a  malaria  subunit  vaccine  is  46 
evident,  as  clinical  symptoms  of  malaria  are  mainly  attributed  to  asexual  blood  47 
stages.  In  exposed  humans  protection  from  symptomatic  disease  is  acquired  after  48 
repeated exposure over years [4]. Naturally acquired immunity is attributed at least  49 
in part to antibody responses targeting blood‐stage antigens. This was demonstrated  50 
by  passive  immunotherapy  studies,  in  which  transfer  of  immunoglobulins  from  51 
immune  individuals  to  malaria  patients  led  to  very  substantial  reductions  of  52 
parasitaemia and clinical symptoms [5–7].   53 
Feasibility of an asexual blood‐stage vaccine is supported by studies in humans and  54 
animal  models  [8–13].  So  far  research  in  this  field  focused  on  a  few  protein  55 
candidates  including  merozoite  surface  protein  1  (MSP‐1)  [14],  MSP‐2  [8],  MSP‐3  56 
[15–18], apical membrane antigen 1 (AMA‐1) [19], erythrocyte binding antigen 175  57 
(EBA175)  [20],  glutamate‐rich protein  (GLURP)  [15,21]  and  serine  repeat  antigen 5  58 
(SERA5)  [22].  These  antigens  are  all  merozoite  proteins,  either  located  on  the  59 
merozoite surface or contained within apical invasion organelles. In contrast to intra‐ 60 
erythrocytic  stages,  which  are  largely  hidden  within  the  red  blood  cells,  free  61 
merozoites are directly accessible to antibodies. Antibodies are thought to interfere  62 
with  the  invasion  of  erythrocytes  by  binding  to  merozoite  surface  proteins  or  63 
proteins  released  from  apical  organelles.  Merozoite  invasion  involves  a  complex  64 





merozoite  to  an  erythrocyte,  the  merozoite  reorients  to  its  apical  pole.  This  67 
interaction  triggers  the  release  of microneme  and  rhoptry  neck  resident  proteins,  68 
which mediate high affinity attachment by the establishment of a tight junction. This  69 
in turn initiates the release of rhoptry bulb resident proteins, which are involved in  70 
the  formation of  a membrane  to  surround  the parasitophorous vacuole. Mediated  71 
by  an  actomyosin  motor  complex  the  tight  junction  is  then  moved  towards  the  72 
anterior  pole,  terminating  with  the  sealing  of  the  parasitophorous  vacuole  73 
membrane at the posterior pole of the merozoite (for a review see reference [25]).  74 
Most  proteins  currently  regarded  as  key  malaria  blood  stage  vaccine  candidate  75 













Thus  far,  relatively  few blood‐stage antigens are  in clinical development as vaccine  89 
components  [33]. Unfortunately,  the most  advanced blood‐stage  vaccine  antigens,  90 
AMA‐1 and MSP‐1, did not demonstrate efficacy  in African children so  far  [34–36].  91 
However,  a  multistage  vaccine  comprising  an  AMA‐1  component  showed  a  50%  92 
reduced incidence rate of clinical malaria episodes in children vaccinees compared to  93 
control  children  [37].  But  whether  protection  is  associated  with  AMA‐1‐specific  94 
responses remains to be shown. The extensive polymorphisms of current candidate  95 
antigens is deemed to be a major hurdle for blood‐stage vaccine development [38– 96 





a  large  range of protein  antigens  in preclinical  assays would allow a more  rational  99 
prioritization of candidates for inclusion into a vaccine. Since the availability of the P.  100 
falciparum  genome  in  2002,  reverse  vaccinology  is  considered  an  opportunity  to  101 
identify  novel  vaccine  candidates  in  a  more  rational  way  [43–51].  Based  on  the  102 
genome‐wide  transcriptomic  and  proteomic  information  generated  since,  we  103 
selected  the  P.  falciparum  open  reading  frame  (ORF)  PFD1130w  for  further  104 




[52]  ii)  a  genome‐wide  in  silico  study  based  on  gene  co‐expression,  sequence  109 
homology,  domain‐domain  and  yeast  two‐hybrid  interaction  data  showed  that  110 
PFD1130w  clustered  into  an  interaction  network  implicated  in merozoite  invasion  111 






In  this  study  we  carried  out  an  in‐depth  characterisation  of  PFD1130w  and  118 
demonstrate  its  potential  as  malaria  asexual  blood  stage  vaccine  candidate.  119 
PFD1130w  is a highly conserved cysteine‐rich protein that we designated Cysteine‐ 120 
rich Protective Antigen  (CyRPA). Our data on  localisation,  stage‐specific  expression  121 
pattern and functional assays suggest a role of CyRPA in erythrocyte invasion by the  122 
merozoite.  Importantly,  CyRPA  elicits  antibodies  that  inhibit merozoite  invasion  in  123 
vitro  and  in  vivo.  Furthermore,  our  passive  immunisation  studies  in  P.  falciparum  124 









Pfd1130w/cyrpa  is  1188  bp  long  with  a  99  bp  intron  and  is  localized  in  the  130 
subtelomeric region of chromosome 4 in close proximity to genes encoding proteins  131 
known to be  involved  in  red blood cell  (RBC)  invasion,  such as  reticulocyte‐binding  132 
protein  homolog  proteins  RH4  and  RH5,  SURFIN4.2  and  glideosome‐associated  133 
protein  with  multiple‐membrane  span  2  (GAPM2)  (Figure  1)  [53–56].  The  134 
hypothetical  protein  encoded  by  pfd1130w  is  predicted  to  contain  a  N‐terminal  135 
secretion signal peptide. Orthologs of CyRPA are only present  in the genomes of P.  136 
knowlesi  (PKH_052740)  and P.  vivax  (PVX_090240)  and  are  absent  in Plasmodium  137 
species  infecting  rodents.  Comparison  of  these  protein  sequences  revealed  138 
conservation with 36% and 38% identity of P. falciparum CyRPA with the P. knowlesi  139 
and  the  P.vivax  orthologs,  respectively.  Furthermore,  cysteine  residues  in  the  140 
orthologs  are  positionally  conserved  (Figure  2).  BLAST  search  identified  the  141 
mosquito‐stage  protein  PSOP12  (PFE0680)  as  paralog  of  CyRPA  [58].  This  protein  142 
















Figure 2. Amino acid sequence alignment of P.  falciparum CyRPA with orthologs  in P. knowlesi and P. vivax.  156 
Full‐length putative orthologs of P.  falciparum CyRPA are only  found  in  the genomes of P. vivax  (PVX_090240)  157 






(Indochina),  Hb3  (Honduras),  Ro‐33  (Ghana),  7G8  (Brazil),  IFA4  (Tanzania),  IFA6  (Tanzania),  IFA10  (Tanzania),  164 












twelve  P.  falciparum  standard  strains  from  different  geographical  origin  (3D7,  K1,  174 
MAD20, FC27, FCR3, RFCR3, W2met, Hb3, Ro‐33, 7G8, ITG2F6 and FVO) and six field  175 
isolates from Tanzania (IFA4, IFA6, IFA10, IFA12, IFA18 and IFA19) were amplified by  176 
PCR  and  sequenced.  Apart  from  one  non‐synonymous  single  nucleotide  177 
polymorphism at base pair position 1116  in P.  falciparum  strains K1,  FCR3,  ITG2F6  178 




The  PFD1130w  gene  encodes  a  362  amino  acid  long  protein  with  a  predicted  183 
molecular mass of 42.8 kDa. Using highly synchronized asexual blood stage parasite  184 
cultures,  we  assessed  the  expression  profile  of  CyRPA  in  P.  falciparum  across  the  185 





staining  of  synchronized  blood  stage  parasites  with  anti‐CyRPA mAbs  (Figure  3B).  191 
These  results  are  in  agreement  with  transcriptional  data  for  PFD1130w,  showing  192 
elevated  transcript  levels  in  late  stages of  the asexual blood cycle of P.  falciparum  193 
with  maximal  expression  measured  at  40  to  48  hours  post‐invasion  [47,48,60].  194 









44, 44‐52: hours post‐invasion; M: free merozoites. (B)  Indirect  immunofluorescence stainings of asexual blood  201 
stage parasites  confirmed  stage  specific  expression  in  schizont  stages  and  free merozoites. Methanol/acetone  202 




CyRPA  has  a  putative  N‐terminal  secretion  signal  sequence  and  is  cysteine‐rich  207 
(Figure 2). No transmembrane domains are predicted and no significant homology to  208 
well  characterized  functional  domains  could  be  identified.  To  determine  the  209 
localisation  of  CyRPA  in  schizont  stages  and  free merozoites more  accurately,  we  210 
performed  co‐localisation  studies  using  antibodies  specific  for  the  cytosol  211 
(glyceraldehyd‐3‐phosphat‐dehydrogenase,  GAPDH),  the  micronemes  (apical  212 





stainings  of  CyRPA  resembled  MSP‐5‐specific  stainings.  Apical  dots  of  MSP‐5  and  218 
CyRPA largely overlayed, but the degree of additional faint staining of the merozoite  219 






Figure  4.  Localisation  of  CyRPA  to  the  merozoite  apex  by  immunofluorescence  staining.  P.  falciparum  3D7  223 
merozoites  (A) or  schizont  stages  (B) were co‐immunostained with anti‐CyRPA mAb c06  (red) and anti‐GAPDH  224 











Considering  the apical  localisation of CyRPA,  and  since CyRPA was predicted  to be  233 
implicated  in  merozoite  invasion  [49],  we  assessed  anti‐CyRPA  mAbs  for  in  vitro  234 
parasite growth inhibitory activity. Growth inhibition assays were conducted for two  235 
cycles  of  merozoite  invasion.  Of  the  anti‐CyRPA  mAbs  tested,  seven  out  of  nine  236 
consistently showed growth inhibitory activity in a concentration dependent manner  237 
(Figure S1).  In contrast,  two anti‐CyRPA mAb  (c05 and c13) as well as control mAb  238 
(6xHis‐tag  specific) had no effect on parasite growth  (Figure 5A and Figure S1). All  239 
mAbs tested were produced and purified in parallel in the same manner and results  240 
were reproducible with independent mAb production batches (data not shown). At a  241 
concentration  of  500  μg/ml  the  anti‐CyRPA mAb  c12  inhibited  parasite  growth  by  242 
65.5  ±  1.7%.  The  growth  inhibitory  effect  was  statistically  significant  for  mAb  243 
concentrations  of  500  (p=0.0006),  250  (p<0.0001)  and  125  μg/ml  (p=0.0030),  as  244 
judged by a two‐sided t test.  245 
In order to identify the step at which the anti‐CyRPA mAbs exert their effect, parasite  246 
growth  was  compared  in  the  presence  or  absence  of  inhibitory mAbs  during  one  247 
blood stage cycle of highly synchronized parasites. 250 μg/ml of the anti‐CyRPA mAb  248 
c12 was added to early ring stages and parasitemia was monitored after 13, 27 and  249 
31  hours  by  flow  cytometry.  No  significant  difference  in  the  development  of  250 
trophozoites from ring stages was observed at any time point compared to the PBS  251 
control  (Figure  5B). When  the  anti‐CyRPA mAb  c12  was  added  to  a  synchronized  252 
parasite  culture  at  the  schizont  stage  and  parasitemia  was  monitored  during  253 
development  into new  ring  and  subsequently  into  trophozoite  stages,  a  significant  254 
reduction  in  parasitemia  compared  to  the  PBS  control  was measured  (Figure  5C).  255 
This reduction emerged as soon as the parasitized erythrocytes had ruptured and the  256 
released merozoites had  infected new erythrocytes  (p=0.0283  for  the difference  in  257 
parasitemia of PBS vs. anti‐CyRPA mAb samples at time point 12 +15h; two‐sided t‐ 258 





that  the  parasite  growth  inhibitory  activity  of  anti‐CyRPA  mAbs  is  not  due  to  261 










added  to  highly  synchronous  schizont  stages  and  parasitemia  was  monitored  during  the  infection  of  new  272 
erythrocytes and the development into ring and trophozoite stages (triangles) and compared to the PBS control  273 
(squares). Parasitemia was measured after 0, 15, 24, 39 and 48 hours.  Each  symbol  represents  the mean of a  274 
duplicate  experiment,  and  error  bars  indicate  the  standard deviation.  Total  parasitemia  is  shown  in  pink,  ring  275 







CyRPA  has  no  orthologs  in  the  rodent  malarial  species  and  therefore  cannot  by  280 
studied  with  conventional  mouse  models  with  rodent  parasites.  Therefore  we  281 
evaluated  the  in  vivo  parasite  inhibitory  activity  of  anti‐CyRPA  mAbs  in  a  P.  282 
falciparum  SCID  mouse  model.  This  model  uses  non‐myelodepleted  NOD‐scid  283 
IL2Rγnull mice engrafted with human erythrocytes in order to allow the growth of P.  284 
falciparum  [66].  Groups  of  three  mice  with  a  parasitemia  of  0.87  ±  0.12  %  were  285 
injected once with 0.5 mg, 2.5 mg or 5 mg anti‐CyRPA mAb c12,  respectively.  The  286 
control  group  received  2.5  mg  subclass‐matched  control  mAb  (6xHis‐tag  specific).  287 
Parasitemia of all mice was monitored for the next five days (Figure 6A). In mice that  288 
had  received  the  control mAb,  a  sigmoidal  increase  in  parasitemia was measured,  289 
reaching  21.0  ±  3.6 %  on  day  6.  Parasitemia  in mice  having  received  2.5 mg  anti‐ 290 
CyRPA  mAb  13,  which  has  shown  no  in  vitro  growth  inhibitory  effect,  increased  291 
similarly. In contrast, parasitemia of mice having received 2.5 mg or 5 mg anti‐CyRPA  292 
mAb c12  increased only marginally, reaching 3.5 ± 1.2 % and 3.7 ± 1.1 % on day 6.  293 
The  difference  in  parasitemia  on  day  6  in  mice  receiving  2.5  mg  of  mAb  c12  294 
compared  to  the  negative  control  group  was  highly  significant  (two‐sided  t‐test;  295 
p=0.0013). Also, a five times  lower dose of mAb c12 (0.5 mg) still  reduced parasite  296 
growth  (15.0 ± 1.2 % parasitemia on day 6). Titration of mAbs  in  the circulation of  297 
the  passively  protected mice  by  ELISA  showed  that  antibody  levels  remained  high  298 
over  the entire  study period,  ranging  from 57‐117 % on day 6 compared  to day 2,  299 
and  immunofluorescence  staining  of  persisting  parasites  showed  that  they  still  300 
expressed CyRPA (data not shown).  301 
On day 6 blood cells of mice having received 2.5 mg anti‐CyRPA mAb c12 were used  302 
in  a  follow‐up  experiment  to  infect  three  naïve  groups  of  NOD‐scid  IL2Rγnull  mice  303 
engrafted with human erythrocytes (Figure 6B). A rapid and continuous  increase  in  304 
parasitemia  indicated  good  viability  of  the  transferred  parasites  (14.7  ±  1.3  %  305 
parasitemia on day 6 in the untreated group). To assess if parasites growing in anti‐ 306 
CyRPA  mAb  c12  treated  mice  (Figure  6A)  have  developed  resistance  to  antibody  307 
inhibition,  recipient  mice  were  treated  with  a  single  i.v.  injection  of  2.5  mg  anti‐ 308 










i.v.  injection. The arrow  indicates  the day of mAb  injection and values are  the mean parasitemia  in peripheral  316 
blood of three mice per group. Data are means ± SD. (B) On day six, blood cells of mice having received 2.5mg  317 










effect  and  seven  (c02,  c04,  c06,  c08,  c09,  c10,  c12)  showed  inhibitory  activity.  To  325 
explain these differences in biological activity, fine specificities of the different mAbs  326 
were analysed. Firstly, antibody‐antibody competition experiments were performed  327 
by  ELISA  using  plates  coated  with  recombinant  CyRPA  protein  expressed  in  E.coli  328 
(Table 1). mAbs c02, c04, c06, c08, c09 and c12 competed against each other. These  329 
mAbs  did  not  compete  with  and  were  not  competed  by mAbs  c05,  c10  and  c13.  330 
While mAbs c05 and c13 competed with each other, mAb c10 did not compete with  331 
and was  not  competed  by  any  of  the  other  anti‐CyRPA mAbs.  According  to  these  332 
results the nine mAbs were grouped into three epitope groups (I, II, III), with the two  333 
non‐inhibitory mAbs forming epitope group III.  334 
Secondly,  the  anti‐CyRPA  mAbs  were  tested  for  their  reactivity  with  overlapping  335 
protein fragments of CyRPA. For this purpose, HEK cells transiently transfected with  336 
expression  plasmids  encoding  fragments  of  CyRPA  comprising  amino  acid  26‐352,  337 
26‐251,  26‐181,  127‐352,  236‐352,  74‐251,  74‐181,  26‐142  and  127‐251  were  338 
analyzed  by  Western  blot  analysis  and  life  cell  staining.  In  Western  blot  analysis  339 
CyRPA‐specific mAbs bound to fragment 26‐181, 26‐251 and 26‐352 but not to the  340 
two overlapping subfragments 26‐141 and 74‐181. This indicates that all nine mAbs  341 
recognize  conformational  epitopes  that  is  present  in  fragment  26‐181,  but  not  342 
formed in subfragments 26‐141 and 74‐181 (Figure S2 and data not shown). Life cell  343 
staining  of  HEK  cells  expressing  the  protein  fragments  on  their  cell  surface  with  344 
different anti‐CyRPA mAbs revealed five distinctive reactivity‐patterns (A, B, C, D, E)  345 
(Table 1). When combining results from antibody‐antibody competition experiments  346 




The  identified  dimorphism  at  amino‐acid  position  339  does  not  lei  within  the  351 


















Figure  7.  Serum  of  some  individuals  from  a malaria  endemic  area  contain  CyRPA  specific  IgG.  Reactivity  of  367 
human  sera  from  Europeans  (unexposed)  or  from West  Afrikans  (malaria  exposed)  with  recombinant  CyRPA  368 
assessed by ELISA. Shown are  IgG  levels expressed as optical density  (OD) at 405 nm of serum samples diluted  369 








 Anti-CyRPA mAb c10 c02 c06 c08 c09 c12 c04 c05 c13 
 Parasite growth inhibition yes yes yes yes yes yes yes no no 
A Antibody-antibody competition ELISA 
  Detecting anti-CyRPA mAb 
 Competing anti-CyRPA mAb c10 c02 c06 c08 c09 c12 c04 c05 c13 
 c10 x − − − − − − − − 
 c02 − x x x x x x − − 
 c06 − x x x x x x − − 
 c08 − x x x x x x − − 
 c09 − x x x x x x − − 
 c12 − x x x x x x − − 
 c04 − x x x x x x − − 
 c05 − − − − − − − x x 
 c13 − − − − − − − x x 
 epitope group I II II II II II II III III 
B Reactivity of anti-CyRRPA mAbs with CyRPA fragments 
  Anti-CyRPA mAb 
 CyRPA fragment  C10 c02 c06 c08 c09 c12 c04 c05 c13 
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With the release of  the  fully annotated genome of P.  falciparum  in 2002, genome‐ 382 
wide  searches  for  potential  vaccine  candidate  antigens  have  become  possible  383 
[45,46].  Based  on  published  transcriptome  and  proteome  data,  suggesting  384 
expression  in extracellular stages and surface  localisation, we have selected sets of  385 
uncharacterized ORFs for evaluation of their potential as vaccine candidate antigens  386 
[47,49,52,57,67]  (and  unpublished  results).  Among  the  proteins  characterized,  387 
CyRPA  exhibited  outstanding  properties,  demonstrating  the  utility  of  systematic  388 
genome‐wide approaches for vaccine antigen selection. However, for each individual  389 




assess  certain  potential  antibody‐mediated  effector  functions  against  blood  stage  394 
parasites  [18,68–70],  i.e.  growth  inhibition  by  antibodies  alone  (GIA)  or  antibody‐ 395 
dependent  cellular  inhibition  (ADCI).  Still,  these  assays  can  provide  valuable  396 
information  on  the  protein  function.  Antibodies  against  CyRPA  showed  a  strong  397 
parasite  growth  inhibitory  activity  in  GIA.  This  activity  targeted  the  process  of  398 
merozoite invasion into RBCs, but not the development of intra‐erythrocytic stages.  399 
These  results  point  towards  a  complement‐  and  leukocyte‐independent  mode  of  400 
action,  such  as  blocking  of  molecular  interactions  involved  in  merozoite  invasion  401 
[26,28].  402 
Plasmodium in vitro cultures are very sensitive to physiological changes. Thus, the in  403 
vitro  growth  inhibition  assay  is  criticized  for  being  very  sensitive  to  impurities  of  404 
antibody  preparations  tested.  We  addressed  this  by  testing  more  than  one  405 
independently  produced  batch  of  the  individual  mAbs  and  obtained  consistent  406 
results.  Importantly,  the mouse  in  vivo  model  offers  the  advantage  of  a  constant  407 
physiological environment given that factors like nutrient supply, electrolyte balance  408 
and pH is very well controlled by the animal [71]. Since P. falciparum cannot  infect  409 




falciparum,  including  CyRPA,  non‐human  primates  or  SCID‐mice  engrafted  with  411 
human erythrocytes are the only in vivo models available to study growth‐inhibitory  412 
effects of CyRPA specific antibodies. It was previously shown that the P. falciparum  413 
model  in  NOD‐SCID  mice  genetically  deficient  in  IL‐2  receptor  γ  chain  (NOD‐scid  414 
IL2Rγnull)  engrafted  with  human  erythrocytes  is  a  reliable  test  system  for  drug  415 
evaluation  in vivo  [66][72]. Also  in our hands, parasite growth  in  infected NOD‐scid  416 
IL2Rγnull mice was very consistent and reproducible. However, this model has never  417 
been  used  previously  for  passive  immunisation  studies.  Anti‐CyRPA  mAbs  418 
administered  at  the  beginning  of  the  exponential  growth  phase  exerted  a  strong,  419 
dose‐dependent parasite growth inhibitory effect. To the best of our knowledge, our  420 
study describes the first immunoglobulin transfer assay using a P. falciparum murine  421 
model  in which a dose‐response relationship has been reported.  In contrast  to  the  422 
previously  described model  [73]  this  system  therefore  permits  comparison  of  the  423 
relative  inhibitory potency of malaria  specific  antibodies  in  vivo.  Thus, we propose  424 
this model as a reliable  in vivo model to test protective efficacy of vaccine antigens  425 
against P. falciparum blood stages.  426 
Growth  inhibitory  capacities  of  different  anti‐CyRPA mAbs  assessed  in  the  in  vivo  427 
model  correlate  with  the  results  obtained  in  the  in  vitro  assays,  strengthening  428 
credibility of both systems. The  inhibitory effect of CyRPA‐specific Abs seen  in vivo  429 
can well be ascribed to the same effector mechanisms as in vitro, namely blocking of  430 
invasion–relevant  processes.  Yet,  we  cannot  exclude  involvement  of  additional  431 













very  slow  rise  in  parasitemia.  Increasing  the  applied  dose  from  2.5  to  5  mg  per  442 
mouse did not reduce multiplication further, indicating a saturation of the inhibitory  443 
mechanism.  From  our  functional  data  we  deduce  that  anti‐CyRPA  mAbs  reduce  444 
parasite  growth  by  partially  inhibiting  some  processes  crucial  for  invasion  of  445 
erythrocytes  by  merozoites,  be  it  a  specific  protein  interaction  or  processing  of  446 
invasion relevant proteins. P. falciparum merozoites are described to use alternative  447 
invasion  pathways  to  evade  antibody  mediated  immunity  [76].  Use  of  a  CyRPA‐ 448 
independent  invasion  pathway  of  limited  efficiency  could  explain  persistence  of  449 
infection associated with a reduced multiplication rate. Since parasites that survived  450 
treatment  with  anti‐CyRPA  mAb  showed  normal  multiplication  rates  when  451 
transferred  into  naive mice,  and  remained  sensitive  to  re‐exposure  to  anti‐CyRPA  452 
mAbs, no  rigid  switch  to an alternative  invasion pathway  seems  to occur.  The  fact  453 
that, at least over a short time period, no CyRPA‐Ab resistant parasites were selected  454 
is  of  importance  when  considering  the  inclusion  of  CyRPA  into  a  malaria  subunit  455 
vaccine.  456 
Interestingly,  among a  set of nine mAbs  specific  for CyRPA,  seven mAbs  showed a  457 
parasite growth inhibiting effect whereas two did not. No confined CyRPA sequence  458 
stretch  could  be  defined  as  epitope,  since  all  mAbs  seem  to  recognize  459 
conformational epitopes not present  in  short CyRPA sequence stretches. However,  460 
the  fine  specificity  of  inhibitory  anti‐CyRPA  mAbs  was  distinct  from  the  fine  461 
specificity of non‐inhibitory anti‐CyRPA mAbs. These results indicate that protection  462 
by  anti‐CyRPA mAbs  is  likely  due  to  blockage  of  a molecular  process  required  for  463 
invasion and not simply due to opsonization. CyRPA thus may be involved in distinct  464 
interactions  with  erythrocyte  structures  and/or  parasite  proteins  involved  in  465 
erythrocyte  invasion.  The  fact  that  only  anti‐CyRPA  antibodies  of  a  certain  fine‐ 466 
specificity  showed  invasion  inhibitory  activity  demonstrates  once  more  the  467 
shortcoming  of  assessing  immunity  or  vaccine‐potential  of  antigens  by  solely  468 
measuring  antibody  titres  by  ELISA.  Besides  CyRPA,  a  range  of  other  blood  stage  469 
antigens,  including AMA‐1 and MSP‐1, where shown to  induce  inhibitory as well as  470 





it  is  favourable  to  perform  passive  immunoprotection  experiments  with  mAbs  in  473 
animal  models  to  identify  novel  vaccine  targets  rather  than  using  active  474 
immunisation. MAbs  represent highly defined agents with a distinct  fine‐specificity  475 
and affinity, whereas immunisation induces antibodies with a wide range of binding  476 
properties.  Hence,  functional  assays  with  polyclonal  antibodies  poses  the  risk  of  477 






to  be  expressed  as  GFP‐fusion  protein  in  order  to  validate  functional  annotations  484 
[49]. In that study, expression of CyRPA as GFP‐fusion protein in transgenic parasites  485 
was  shown  to  result  in  a  predominantly  apical  distribution.  Consistent  with  this  486 
finding  we  showed  by  indirect  immunofluorescence  staining  with  CyRPA‐specific  487 
mAbs  that CyRPA  localises at  the merozoite apex. Additionally we could show that  488 
CyRPA  does  not  localize  to  micronemes  or  rhoptries.  The  CyRPA‐specific  staining  489 
showed similarity to the staining of MSP‐5, possibly indicating that CyRPA shares the  490 
same subcellular  localisation as MSP5, a protein considered as blood stage vaccine  491 
candidate  [79,80]. Although MSP‐5  is  described as  a merozoite  surface protein,  its  492 






surface  antigens  as  a  result  of  natural  selective  pressure  by  the  human  immune  499 
responses  [83].  Most  of  the  asexual  blood‐stage  vaccine  candidates  evaluated  to  500 
date, including AMA‐1, MSP‐1 and MSP‐2, therefore have substantial polymorphisms  501 
[39–42].  Immunodominance  of  the  polymorphic  and  variant  epitopes may  explain  502 





polymorphic  antigens  run  the  risk  of  compromised  efficacy  due  to  selection  of  505 
vaccine‐resistant variants [8]. Therefore, it may be desirable to focus on antigens and  506 
protein  domains  with  limited  polymorphism.  Only  some  of  the  sera  of  malaria‐ 507 
exposed adults tested here contained CyRPA specific Abs; natural immunogenicity of  508 
CyRPA  thus appears  to be  limited. Our  sequence analysis  revealed  that CyRPA  is  a  509 
highly conserved protein. Only a single non‐synonymous SNP was detected among a  510 
range  of P.  falciparum  isolates.  This,  together with  the  low  immunogenicity,  is  an  511 
indication that CyRPA  is not a major target of naturally acquired immune responses.  512 
Furthermore,  the  identified  SNP‐associated  amino  acid  dimorphism  is  not  located  513 
within  the  epitope  of  the  growth‐inhibitory  anti‐CyRPA  mAbs  and  their  growth  514 
inhibitory effect was not affected by this dimorphism (data not shown). From these  515 
results we deduce that the protection‐associated epitope of CyRPA is entirely free of  516 
polymorphisms,  suggesting  that  a  CyRPA‐based  vaccine would  target  the  entire P.  517 
falciparum population. This represents a clear advantage compared to polymorphic  518 
vaccine  antigens  like  AMA‐1,  where  several  studies  showed  significant  allele‐ 519 
specificity in the inhibitory activity of anti‐AMA‐1 antibodies [85–87].  520 




presence  of  total  CyRPA‐specific  antibody  titres  in  human  sera  is  not  sufficient  to  525 




suitability  as  candidate  antigen  for  inclusion  into  a  multivalent  malaria  subunit  530 
vaccine. In addition we adopted the improved P. falciparum mouse model based on  531 
NOD‐scid IL2Rγnull mice for functional analysis of malaria blood stage antibodies. This  532 








Protection  of  Animal  Rights  (Tierschutzverordnung)  of  the  Swiss  Bundesamt  für  538 
Veterinärwesen. The protocol was ethically approved by the Ethikkommission beider  539 
Basel (Permit Number: 2375). Human sera were obtained from adult volunteers after  540 
receiving  written  informed  consent.  Ethical  clearance  was  obtained  from  the  541 
Ethikkommission beider Basel.  542 
Culture of parasites  543 
P.  falciparum  strain  3D7 was  cultured essentially  as  described previously  [89].  The  544 
culture medium was  supplemented with 0.5% AlbuMAX  (Gibco) as a  substitute  for  545 
human  serum  [90].  Cultures  were  synchronised  by  sorbitol  treatment  [91].  546 
Erythrocytes for passages were obtained from the Swiss Red Cross (Switzerland).  547 
Isolation of free merozoites  548 
To obtain P.  falciparum merozoites,  erythrocytes  infected with highly  synchronous  549 
schizont‐stage  parasites were  centrifuged  at  700  g  for  5 min  to  separate  released  550 
merozoites  from  unruptured  schizonts  and  uninfected  erythrocytes.  Supernatants  551 
containing  free  merozoites  were  centrifuged  at  3000  g  for  10  min  to  collect  552 
merozoites.  553 
Western blot analysis  554 
Blood  stage  parasite  lysates  were  prepared  essentially  as  described  previously  by  555 









For  SDS‐PAGE  cell‐  or  parasite  lysate was  resolved  on  precast  4‐12%  gradient  gels  562 
(NuPAGE® Novex 4‐12% Bis‐Tris Gel,  Invitrogen) with MES running buffer according  563 
to  the manufacturer’s directions. The proteins were electrophoretically  transferred  564 
to  nitrocellulose  membrane  using  a  dry‐blotting  system  (iBlot,  Invitrogen).  After  565 
blocking the membrane, specific proteins were detected with appropriate dilutions  566 
of  anti‐CyRPA  mAbs  [57]  or  anti‐hexa‐his‐tag  mAb  [57]  followed  by  horseradish  567 
peroxidase‐conjugated goat anti‐mouse IgG mAb (Kirkegaard & Perry Laboratories).  568 
Blots were developed using ECL Western blotting detection  reagents  (ECL Western  569 
Blotting Substrate, Pierce).  570 
Immunofluorescence staining of infected erythrocytes and free merozoites  571 
For  indirect  immunofluorescence  microscopy,  smears  of  infected  red  blood  cells  572 
were fixed  in 60% methanol and 40% acetone for 2 min at −20°C and blocked with  573 
1% BSA in PBS. Isolated free merozoites were spotted and fixed onto L‐lysine coated  574 
multitest  glass  slides  as  described  previously  [92].  Cells  were  probed  with  the  575 
following  primary  or  secondary  antibodies:  biotin‐labeled  mouse  anti‐CyRPA  mAb  576 
c06 [57], Alexa488‐labeled mouse anti‐RAP‐1 5‐2 mAb [93], Alexa488‐labeled mouse  577 
anti‐AMA‐1  DV5a  mAb  [92],  Alexa488‐labeled  mouse  anti‐MSP‐1  MC7.2  mAb  578 
(unpublished),  Alexa488‐labeled  mouse  anti‐GAPDH  1.4a  mAb  [94],  anti‐MSP‐2  579 
rabbit  serum  (Malaria  Research  and  Reference  Reagent  Resource  Center  (MR4),  580 
MRA‐318),  anti‐MSP‐4  rabbit  serum  [95],  anti‐MSP‐5  rabbit  serum  [81],  Alexa568‐ 581 
labeled streptavidin (Invitrogen) and Alexa488‐labeled chicken anti‐rabbit  IgG (H+L)  582 
(Invitrogen).  The  slides  were  mounted  in  mounting  medium  containing  DAPI  583 
(ProLong Gold antifade reagent with DAPI, Invitrogen). Fluorescence microscopy was  584 




In  vitro  growth  inhibition  assays  with  P.  falciparum  strain  3d7  were  conducted  589 
essentially  as  described  [92].  Each  culture  was  set  up  in  triplicate  in  96‐well  flat‐ 590 
bottomed  culture  plates.  Viable  parasites  were  stained  with  hydreothidine  and  591 




CellQuest  software.  A  total  of  30’000  cells  per  sample  were  analysed.  Percent  593 
inhibition was  calculated  from  the mean  parasitemia  of  triplicate  test  and  control  594 
wells; (control – test)/(control/100).  595 
In vivo growth inhibition assay  596 
Antibodies were  tested  in  the murine P.  falciparum model essentially as described  597 











For  the  analysis  of  human  sera  for  presence  of  CyRPA‐specific  antibodies,  plates  609 
were  coated  with  10  µg/ml  purified  recombinant  CyRPA  protein.  After  blocking,  610 






Plates  were  coated  with  10  µg/ml  purified  recombinant  CyRPA  protein.  After  617 
blocking, plates were incubated with 10 µg/ml, 1 µg/ml or 0 µg/ml of different anti‐ 618 
CyRPA  mAbs  (c02,  c04,  c05,  c06,  c08,  c09,  c10,  c12,  c13).  After  30  min  different  619 
biotinylated anti‐CyRPA mAbs (c02, c04, c05, c06, c08, c09, c10, c12, c13) are added  620 






used  for development. The  reaction was  stopped with 0.5M H2SO4 and  the optical  624 
density (OD) was measured at 450 nm.  625 
Culture of eukaryotic cells  626 
The  human  embryonic  kidney  cell  line  293  HEK  was  obtained  from  the  American  627 








Fr74‐181;  3938  &  3939,  Fr74‐251;  3938  &  3913  (Table  S1).  Amplifications  were  636 
performed  using  FIREPol  DNA  polymerase  (Solis  Biodyne)  according  to  the  637 
manufacturers protocol with the following profile: 5 min 95°C; 30 x (30 s 95°C, 30 s  638 
60°C,  2  min  72°C);  6  min  72°C.  The  amplicons  were  digested  with  restriction  639 
endonucleases  NheI  and  NotI  (New  England  Biolabs),  and  then  ligated  into  a  640 
pcDNA3.1‐based expression vector. This expression vector allows surface expression  641 
of  a  protein  of  interest.  It  contains  the  secretion  signal  of  bee‐venom mellitin,  a  642 
cloning  site  for  the  protein  of  interest,  a  FLAG‐tag,  a  transmembrane  domain  of  643 
mouse glycophorine‐A and a hexa‐his  tag.  The  two  tags  are positioned  just before  644 
and  after  the  transmembrane  domain  to  facilitate  verification  of  the  extracellular  645 
localisation of the recombinantly expressed antigens. 293 HEK cells were transfected  646 
with  the different expression vectors using  JetPEITM  transfection  reagent  (PolyPlus)  647 








later  transfected  with  different  expression  vectors.  The  following  day  653 
immunofluorescence  stainings  were  performed  by  incubating  the  wells  with  100  654 
μg/ml mAb diluted in IMDM for 30 min on ice.  After washing, cells were fixed for 30  655 
min with 4%  formaldehyde  in PBS. After washing,  cells were  incubated  for 30 min  656 







for  recombinant  expression  of  CyRPA  protein.  Bacteria were  grown  in  LB medium  664 
containing 100 μg/ml ampicillin.  665 
Recombinant protein expression and purification  666 







BL  21  Star  (DE3)  (Invitrogen)  was  induced  by  addition  of  1mM  isopropyl  674 








20mM  Tris‐HCl,  5mM  Imidazole)  and  sonicated.  The  lysate  was  cleared  by  680 
centrifugation and the supernatant was  loaded onto a Ni‐NTA column. The column  681 
was washed with binding buffer  and  the hexa‐histidine‐taged  recombinant protein  682 
was recovered using elution buffer (8M urea, 500mM NaCl, 20mM Tris‐HCl, 500mM  683 
imidazole). The purity and integrity of the purified protein was analyzed by SDS‐PAGE  684 




Genomic DNA was prepared  from P.  falciparum  strains 3D7, MAD20, FC27, RFCR3,  689 
W2met, Hb3, Ro‐33, 7G8, K1 FCR3, ITG2F6, FVO, IFA4, IFA6, IFA10, IFA12, IFA18 and  690 
IFA19  and  used  for  PCR  amplification  of  PFD1130w.    PFD1130w  was  amplified  in  691 
three overlapping fragments with the following primer combinations: 3888 & 3899,  692 
3896  &  3903,  3900  &  3891  (Table  S1).  Amplifications  were  performed  using  693 
DreamTaq  DNA  polymerase  (Fermentas  Life  Sciences)  according  to  the  694 
manufacturers protocol with the following profile: 5 min 95°C; 35 x (30 s 95°C, 30 s  695 
60°C,  2  min  72°C);  6  min  72°C.  Amplicons  were  purified  and  subjected  to  direct  696 




(http://plasmodb.org/plasmo/)  with  following  accession  numbers:  P.  falciparum  701 
CyRPA (PFD1130w), P. vivax CyRPA (PVX_090240), P. knowlesi CyRPA (PKH_052740),  702 
P.  falciparum  MSP‐1  (PFI1475w),  P.  falciparum  MSP‐2  (PFB0300c),  P.  falciparum  703 
MSP‐3  (PF10_0345),  P.  falciparum  MSP‐4  (PFB0310c),  P.  falciparum  MSP‐5  704 
(PFB0305c), P. falciparum AMA‐1 (PF11_0344), P. falciparum EBA‐175 (MAL7P1.176),  705 
P.  falciparum  GLURP  (PF10_0344),  P.  falciparum  SERA5  (PFB0340c),  P.  falciparum  706 
RH4  (PFD1150c),  P.  falciparum  RH5  (PFD1145c),  P.  falciparum  SURFIN4.2  707 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 thank  Bernard  Rutten  for  antibody  purification  and  Caroline  Kulangara  for 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Supplementary Figure 1. Some, but not all anti‐CyRPA mAbs  inhibit parasite growth  in vitro.  Synchronous P.  718 
falciparum 3D7 blood stage parasites were cultured for two cycles in the presence of different concentrations of  719 
purified  anti‐CyRPA  mAbs.  Percent  parasite  growth  inhibition  was  calculated  against  the  parasitemia  of  PBS  720 
control  wells.  Anti‐6xHis‐tag mAb was  used  as  negative  control mAb.  Each  symbol  represents  the mean  of  a  721 
triplicate experiment, and error bars indicate the standard deviation.   722 
  723 
Supplementary  Figure  2.  Reactivity  pattern  of  anti‐CyRPA  mAb  c12  with  fragments  of  the  target  antigen.  724 
Lysates of HEK cells transiently transfected with expression plasmids encoding different CyRPA protein fragments  725 
were probed with anti‐CyRPA mAbs. All nine mAbs recognized fragment 26‐352 (dark pink), and all except mAb  726 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in  vivo,  but  this  approach  has  in  the  case  of  the  Plasmodium  falciparum malaria  1052 
infection  only  rarely  been  used,  since  the  human  malaria  parasites  cannot  infect  1053 
rodent  erythrocytes.  Here  we  describe  passive  antibody  protection  studies  in  1054 
immuno‐compromised  NOD‐scid  IL2Rγnull mice  engrafted with  human  erythrocytes  1055 
and  infected  with  P.  falciparum.  We  show  that  the  growth  inhibitory  effect  of  1056 
antibodies  specific  for  the  P.    falciparum  blood  stage  antigen  CyRPA  varies  with  1057 
parasite  density.  Complement  depletion  experiments  demonstrate  that  the  1058 
complement  system  augments  the  anti‐parasitic  effect,  but  is  not  strictly  required  1059 
for  antibody  mediated  growth  inhibition.  These  results  qualify  the  P.    falciparum  1060 







Naturally  acquired  antibodies  specific  for  malaria  blood  stage  parasites  are  1064 
efficacious  in  the  prevention  of  malaria  disease,  as  shown  by  passive  transfer  1065 
experiments in humans [1‐4]. The specificity of the antibodies that confer protection  1066 
against malaria as well as the mechanisms by which antibodies mediate protection  1067 
are  not  fully  characterized.  A  variety  of  mechanisms  by  which  antibodies  may  1068 
potentially  prevent  disease  have  been  suggested  include  i)  blocking  of  the  1069 






dispersal  [22,23],  viii)  prevention  of  processing  of  invasion  proteins  [24]  or  ix)  1076 
blocking of merozoite  invasion [15,25‐29].  It appears that the mechanism by which  1077 
antibodies inhibit parasite growth depends on the nature of the antigen.  1078 
A  range  of  in  vitro  assays  have  been  developed  trying  to  assess  the  various  1079 
mechanisms of antibody‐based protection against malaria [8,10,11,20,21,24,30‐33].  1080 
The most broadly used assays measure the growth inhibitory effects of immune sera  1081 
or purified antibodies alone [32] or  in co‐operation with human monocytes [33].  In  1082 
vitro  assays  are  criticized  for  being  very  fragile,  prone  to  contaminating  parasite‐ 1083 
inhibitory  substances  and  of  poor  reproducibility  [34].  Additionally  there  are  1084 
contradictory results about the correlation of in vitro inhibitory activity of antibodies  1085 
and protection  in  animals  or  humans  [35‐37].  In  this  regard,  in  vivo  assays  for  the  1086 
analysis  of  antibody  functions  are  considered more  reliable  [38].  Several  different  1087 
mouse models have been used to investigate the in vivo protective role of antibodies  1088 
specific  for  antigens  of  rodent malarial  parasite  species  [39,40].  Assessment  of  P.  1089 
falciparum  specific  antibodies  either  has  relied  on  mice  infected  with  genetically  1090 
modified rodent malarial parasite species expressing the P. falciparum target antigen  1091 




immuncompromised  mice  engrafted  with  human  erythrocytes,  which  support  1093 
infection  with  P.  falciparum,  permit  assessment  of  the  protective  role  of  specific  1094 
antibodies  [43,44].  Experiments  using  human  erythrocyte  engrafted  BXN  mice  1095 
depleted  in  tissue  macrophages  showed  growth  inhibitory  activity  of  passively  1096 
transferred human antibodies specific  for merozoite surface protein 3  (MSP3)  [43].  1097 
This  effect was  dependent  on  concomitant  reconstitution with  human monocytes,  1098 
indicating  a  monocyte‐dependent  inhibitory  machanism  of  anti‐MSP3  antibodies.  1099 
Our  antibody  transfer  experiments  with  human  erythrocyte  engrafted  NOD‐scid  1100 
IL2Rγnull mice showed a growth inhibitory effect of mouse antibodies specific for the  1101 
recently  characterized cysteine‐rich protective antigen  (CyRPA)  [44].  In  comparison  1102 
to  the  BXN  mouse  model  the  NOD‐scid  IL2Rγnull  mouse  model  features  more  1103 
consistent  infection  with  P.  falciparum  due  to  superior  engraftment  with  human  1104 
erythrocytes  [45].  Consequently  this  model  showed  improved  reproducibility  and  1105 




immune  protection  by  anti‐CyRPA  mAbs.  For  the  analysis  of  the  effect  of  1110 
complement, we complement depleted mice by treatment with cobra venom factor  1111 
(CVF).  CVF  is  a  functional  analog  of mammalian  complement  component  C3b,  the  1112 
active  fragment of  C3  [46].  Both CVF  and C3b  can bind  factor B  and  subsequently  1113 
form  the  bimolecular  C3/C5  convertases  CVF,Bb  or  C3b,Bb,  respectively.  The  two  1114 
homologous  enzymes  exhibit  a  difference  in  physico‐chemical  stability,  allowing  1115 
continuous  activation  of  C3  and  C5  by  CVF,Bb,  leading  to  serum  complement  1116 
depletion.  Furthermore  we  assessed  the  influence  of  the  time  point  of  1117 
administration  on  passive  immune protection  by  anti‐CyRPA mAbs  and  the  in  vivo  1118 







Growth  inhibitory effect of anti‐CyRPA mAbs  in relation to the parasitemia  1122 
level  1123 
It  was  shown  previously  that  anti‐CyRPA mAbs  exert  a  parasite  growth  inhibitory  1124 
activity in P. falciparum  infected NOD‐scid IL2Rγnull mice [44]. Here we assessed the  1125 
parasite  growth  inhibitory  effect  of  anti‐CyRPA  mAbs  when  administered  either  1126 
before  infection of mice, at  low parasitemia, or at high parasitemia  (Figure 1). The  1127 
group of mice having  received a  single dose of 2.5mg anti‐CyRPA mAb 12 one day  1128 




control  group  from  day  3  onwards  (0.53±0.15%  vs.  6.67±01.35%  on  day  6,  T‐test  1133 
p=0.001).  In  the group of mice having  received a single dose of 2.5 mg anti‐CyRPA  1134 
mAb 12 at  a parasitemia of  0.53±0.06%, parasitemia  increased only  slightly during  1135 
the  next  five  days  to  1.87±0.40%,  which  was  significantly  lower  compared  to  the  1136 










by  iv  injection.  Arrows  indicate  the  day  of  antibody  administration;  one  day  before  infection  (pink),  at  low  1144 
parasitemia  (yellow)  or  at  high  parasitemia  (green).  Data  of  figure  A)  and  B)  were  achieved  in  independent  1145 
experiments. Values are the mean parasitemia ± SD in peripheral blood of three mice per group.   1146 
  1147 
Role  of  complement  for  the  in  vivo  parasite  growth  inhibitory  activity  of  1148 
anti‐CyRPA mAbs  1149 
Anti‐CyRPA mAbs  inhibit  parasite  growth not  only  in  a mouse model  but  also  in  a  1150 
parasite  growth  inhibition  assay  (GIA)  using P.  falciparum  in  vitro  cultures without  1151 
addition of phagocytes [44]. Hence anti‐CyRPA mAbs have a direct in vitro red blood  1152 
cell  invasion inhibitory activity [44], which is  independent of additional elements of  1153 
the  immune system,  like complement and  immune cells. Nevertheless such  factors  1154 
may  enhance  in  vivo  growth  inhibitory  activity  of  anti‐CyRPA mAbs.  To  assess  the  1155 
potential  impact  of  complement,  we  performed  passive  immunisations  of  P.  1156 







in mice  depleted  of  complement was  higher  compared  to  non‐depleted mice,  but  1161 
this  difference was  not  significant  (16.53±2.30%  vs.  13.40±3.77%,  T‐test  p=0.287).  1162 
The  dose  dependent  and  statistically  significant  growth  inhibitory  effect  of  anti‐ 1163 
CyRPA mAb 12 was observed in both complement‐depleted and non‐depleted mice.  1164 
But parasitemia on day 6 was significantly higher  in CVF‐treated mice compared to  1165 
non‐treated  mice,  indicating  that  complement  enhances  the  inhibitory  activity  of  1166 
ant‐CyRPA mAbs. Treating mice with 2.5mg anti‐CyRPA mAb increased the parasite  1167 




Figure  2.  Parasite  growth  inhibitory  effect  of  anti‐CyRPA mAbs  in  complement depleted mice. P.  falciparum  1172 
infected NOD‐scid IL2Rγnull mice received 0.5mg (green) or 2.5mg (yellow) purified anti‐CyRPA mAb 12 or just PBS  1173 
(black)  by  iv  injection.  Three  groups  of  mice  (closed  symbols)  were  complement  depleted  by  intraperitoneal  1174 
injections  of  5  units  cobra  venom  factor  (CVF)  7h  and  3h  before  antibody/PBS  injection  and  daily  thereafter  1175 











These  include  the  apical  membrane  antigen  1  (AMA‐1),  the  merozoite  surface  1184 
protein 3 (MSP‐3) and D13 [47‐49]. Here we assessed monoclonal mouse antibodies  1185 
specific  for  these  antigens  for  their  in  vivo  growth  inhibitory  capacities  (Figure  3).  1186 
Mice  with  a  mean  parasitemia  of  0.64±0.10  received  a  single  intravenous  1187 






Figure  3.  In  vivo  growth  inhibitory  activity  of  mAbs  specific  for  different  malaria  blood  stage  antigens.  P.  1194 
falciparum  infected NOD‐scid  IL2Rγnull mice received a single  intravenous  injection of purified mAbs specific for  1195 
D13  (red), AMA‐1  (green), MSP‐3  (purple) or CyRPA  (yellow).  Control mice  received mock  treatment with PBS  1196 
(black). Parasitemia was measured over the next five days. Values are the mean parasitemia ± SD in peripheral  1197 








of  parasites  and  symptoms  was  as  fast  or  faster  than  with  drugs.  Passive  1203 
immunisation of P. falciparum infected NOD‐scid IL2Rγnull mice with monoclonal anti‐ 1204 
CyRPA  antibodies  either  resulted  in  a  stagnation  in  parasitemia  when  antibodies  1205 
were  administered  at  0.5%  parasitemia  or  a  transient  but  moderate  decrease  in  1206 
parasitemia  when  admininstered  at  4%  parasitemia.  In  passive  immunisation  1207 
experiments  with  MSP3‐specific  human  antibodies  a  more  profound  decrease  in  1208 
parasitemia has been described [43]. Whether these difference are due to inherent  1209 
differences  of  the  protective  mechanisms  of  the  antibodies  or  due  to  profound  1210 
differences in the animal models used remains to be addressed.   1211 
Passive  transfer  of  anti‐CyRPA  mAbs  one  day  before  infection  of  mice  did  not  1212 
prevent establishment of infection but after 5 days had a significant inhibitory effect  1213 
on  the  course  of  parasitemia.  In  summary our  data  shows  the higher  parasitemia,  1214 
the  stronger  the  growth  inhibitory  action  of  anti‐CyRPA  mAbs.  Mechanisms  1215 
explaining  this effect  remain to be  identified. Additionally,  so  far only  the effect of  1216 
monoclonal antibodies was assessed. But considering CyRPA as a malaria blood stage  1217 
vaccine antigen,  it will  be  important  to assess  the  inhibitory  capacity of polyclonal  1218 
CyRPA‐specific  antibodies.  However,  the most  important  question  remained  to  be  1219 




Innate  immune  factors  play  a  crucial  role  in  reducing  the  parasite  load  in malaria  1224 
infections. On the other hand host innate responses were found to contribute to the  1225 
pathophysiology  of  severe  malaria  [50].  One  component  of  the  innate  immune  1226 
system found to be important during malaria  infections  is the complement system.  1227 
Human malaria patients were shown to have decreased serum concentrations of C3  1228 





were  shown  to  activate  the  alternative  complement  pathway.  In  the  presence  of  1231 
parasite‐specific antibodies, activation was augmented by the classical pathway [11],  1232 
leading to C3b binding to the  infected erythrocyte. Surface bound complement did  1233 
not  result  in  cell  lysis  but  possibly  facilitates  opsonization  and  elimination  of  the  1234 
infected  cells by phagocytes. Additionally,  certain antibodies  specifically binding  to  1235 
the  surface  of merozoites were  found  to  exert  a  complement  dependent  parasite  1236 
growth  inhibitory  action,  probably  by  causing  complement‐mediated  damage  of  1237 
merozoites  [20].  Hence, merozoite  antigens may  generally  be  targets  of  antibody‐ 1238 
mediated  activation  of  complement.  This  assumption  is  in  agreement  with  the  1239 
finding that the decrease  in serum concentrations of C3 and C4  in malaria patients  1240 
occurs at the time of merozoite invasion [52,53].  1241 
Complement  depletion  of  P.  falciparum  infected  NOD‐scid  IL2Rγnull  mice  had  no  1242 
significant effect on the course of infection. This indicates that potential activation of  1243 
the alternative complement pathway had no marked effect on the parasitemia. The  1244 
inhibitory  effect  of  anti‐CyRPA  mAbs  was  observed  irrespective  of  whether  the  1245 
complement  system was  intact  or  depleted.  These  results,  together  with  the  fact  1246 
that anti‐CyRPA mAbs also  inhibit parasite growth  in  vitro  in absence of additional  1247 
elements of the  immune system [44], prove that the  inhibitory mechanism of anti‐ 1248 
CyRPA mAbs is independent of complement. However, the in vivo inhibitory effect of  1249 
anti‐CyRPA  mAbs  was  diminished  by  complement  depletion,  indicating  that  the  1250 
complement system in combination with the antibodies exerts some parasite growth  1251 
inhibition  enhancing  effect.  Anti‐CyRPA  mAbs  were  shown  to  retard  merozoite  1252 
invasion  [44].  Consequently  hampered  merozoites  with  bound  anti‐CyRPA  mAbs  1253 
possibly activate the classical complement pathway resulting in the opsonization of  1254 
merozoites, which could further reduce the invasion success of the merozoites.  1255 
Having  shown  that  complement  enhances  but  is  not  a  strict  prerequisit  for  the  1256 
inhibitory  effect  of  CyRPA  antibodies,  the  question  remains  open  as  to  whether  1257 
other  immune  factors  are  involved  in  anti‐CyRPA  mediated  effect  in  vivo.  Hence,  1258 








these  antigens  tested  by  passive  immunsiation  of P.  falciparum  infected NOD‐scid  1264 
IL2Rγnull mice showed no growth inhibitory effect  in vivo. A possible explanation for  1265 
this discrepancy could be that the tested mAbs have the wrong fine specificity. For  1266 
several  blood  stage  antigens  it  has  been  shown  that  the  fine  specificity  of  the  1267 
antibodies  is  crucial  for  their  functionality  [54,55]. Notwithstanding  the above,  the  1268 
remarkable  results  obtained  with  antibodies  specific  for  the  merozoite  protein  1269 








Antibodies were  tested  in  the murine P.  falciparum model essentially as described  1274 
[56].  The  only  modification  implemented  was  that  daily  human  blood  injections  1275 
(0.75ml) were administered by the intravenous route instead of the intraperitoneal  1276 
route. Mice  received  a  single  dose  of monoclonal  antibody  in  PBS  by  intravenous  1277 
injection either one day before infection or when parasitemia was approximately 0.5  1278 
or 4%. To deplete complement mice received 5 units of purified cobra venom factor  1279 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Among  protein  classes  of  Plasmodia  the  family  of  6‐cysteine  proteins  has  gained  1488 
major  interest  in  malaria  research.  6‐cysteine  proteins  are  characterized  by  the  1489 
presence  of  one  or  several  s48_45  domains,  containing  six  positionally  conserved  1490 
cysteine  residues,  which  are  predicted  to  form  disulfide  bridges  resulting  in  a  β‐ 1491 
sandwich structure. Various members are characterized as surface  ligands  involved  1492 
in cell‐cell interaction. Individual 6‐cysteine proteins were shown to be implicated in  1493 
liver stage development, merozoite invasion or parasite fertilization. Of 11 members  1494 
encoded  by  the  genome  of  P.  falciparum,  PFF0620c/Pfs12p  has  not  yet  been  1495 
characterized.  In  the  present  study  we  used  specific  antibodies  to  look  at  the  1496 
expression  of  PFF0620c  at  the  protein  level  in  different  life‐cycle  stages  of  P.  1497 
falciparum.  By  immunofluorescence  staining  protein  expression  of  PFF0620c  was  1498 
detected  in  stage  I  to  stage V gametocytes and  salivary gland derived  sporozoites.  1499 
However, partly conflicting results attained by western blot analysis of stage specific  1500 
lysates  calls  for  further  experiments.  The  tentative  stage  specific  expression  of  1501 
PFF0620c  in  gametocytes  and  sporozoites  suggests  a  possible  role  in  fertilization,  1502 
penetration of mosquito gut lining, sporozoite motility or hepatocyte invasion. In this  1503 








The  parasite  undergoes  a  complicated  life  cycle  involving  a  mosquito  of  the  1508 
anopheles  genus  as  primary  host  and  transmission  vector  and  a  vertebrate  as  1509 
secondary host. For the major part of the life cycle the parasite remains intracellular,  1510 
developing  within  hepatocytes  and  erythrocytes  of  the  vertebrate  host.  Only  the  1511 
merozoite,  the  form  that  invades  erythrocytes,  the  gamete,  developing  from  1512 
intracellular  gametocytes  upon  ingestion  by  a  mosquito,  the  ookinete  and  oocyst  1513 
that result from gamete fertilisation, and the sporozoite, the form that is introduced  1514 
by  a  mosquito  bite  and  subsequently  invades  liver  cells,  are  extracellular.  These  1515 
extracellular  stages undergo highly  specific  cell‐cell  interactions; merozoites  invade  1516 
erythrocytes,  sporozoites  invade  hepatocytes,  male  and  female  gametes  fuse  for  1517 
fertilisation  and  ookinetes  penetrate  the  gut  lining  of  the  mosquito.  All  these  1518 
processes  depend  on  highly  specific  interactions  of  cell‐surface  proteins.  As  a  1519 
consequence, surface proteins and proteins released to the cell surface from apical  1520 
secretory  organelles  upon  invasion  of  extracellular  stages  are  of  major  scientific  1521 
interest, as  they present the key to understand the complex processes of parasite‐ 1522 
host/parasite‐parasite  cellular  interactions.  Besides,  these  molecules  present  the  1523 
Achilles’  heel  of  malaria  infection.  Therefore  it  is  no  surprise  that  most  malaria  1524 
vaccine antigens under development are surface proteins or proteins released from  1525 
apical secretory organelles of extracellular stages [1].  1526 
Among  protein  classes  of  Plasmodia  the  family  of  6‐cystein  proteins  has  gained  1527 
major  interest  in  malaria  research.  Members  of  the  6‐cysteine  protein  family  are  1528 
exclusively found in Apicomplexan species. 6‐cysteine proteins are characterized by  1529 
the presence of one or  several  s48_45 domains. These domains are approximately  1530 
120  amino  acids  in  size  and  contain  six  positionally  conserved  cysteine  residues,  1531 
which are predicted to form disulfide bridges resulting in a β‐sandwich structure [2].  1532 
The Plasmodium  genomes  encode  11 members  of  this  protein  family.  All  of  them  1533 
have  a  secretion  signal  peptide  and  8  are  predicted  to  be  GPI  anchored  [3‐5],  1534 




experimentally  that  they  locate  to  the  parasite  surface  or  within  apical  secretory  1536 
organelles. Additionally they were found to be expressed exclusively in one specific  1537 
extracellular  parasites  stage  [3,6‐15].  Consequently  they  got  considered  to play  an  1538 
important  role  in  cell‐cell  interactions.  This  was  shown  for  the  gamete  surface  1539 
protein  P48/45,  the  male  gamete  surface  protein  P230  and  the  female  gamete  1540 
surface  protein  P47,  which  were  found  to  be  essential  for  parasite  fertilization  1541 
[6,16,17].  Additionally,  antibodies  specific  for  P48/45  [12,18,19]  and  P230  [20‐24]  1542 
were  shown  to  prevent  zygote  formation  and  thus  block  transmission  of  the  1543 
parasites.  Furthermore,  deletion  of  the  sporozoite  proteins  P52/P36p  and/or  P36  1544 
resulted in aborted development in hepatocytes [9,25‐27]. Immunisation with these  1545 
mutant  sporozoites  induced  protective  immune  responses  against  challenge  with  1546 
wild‐type sporozoites in rodent models [9,25]. Four 6‐cysteine proteins expressed in  1547 
late asexual stages, P12, P38, P41 and P92, were found to localize to the merozoite  1548 
surface  or  to  apical  secretory  organelles  [3,5].  Pf92 was  found  to  be  refractory  to  1549 
genetic  deletion,  suggesting  that  it  plays  an  important  role  in  blood‐stage  1550 
development  [28].  For  all  four  6‐cystein  proteins  expressed  in  merozoites  1551 
erythrocyte binding peptides were identified, which inhibited merozoite  invasion  in  1552 
vitro,  suggesting  a  possible  role  of  these  proteins  during  erythrocyte  invasion  1553 
[29,30].  Taken  together,  studies  of  different  6‐cystein  proteins  either  proved  or  1554 
suggested  a  function  in  cell‐cell  interaction.  Accordingly  some  of  them  are  1555 
considered promising malaria vaccine candidate antigens [24,31].  1556 
However,  there  is  one  member  of  the  predicted  6‐cystein‐protein  family  of  1557 
Plasmodium  falciparum  that  has  not  yet  been  characterized  at  all;  PFF0620c,  1558 
sometimes referred as Pfs12p due to its close proximity to Pfs12. No transcipt data is  1559 
available  for PFF0620c except  for asexual blood stages, where  transcript  levels are  1560 
consistently low. But by mass spectrometry the protein has been detected in oocyst  1561 
derived  P.  falciparum  sporozoites  [32].  By  contrast,  its  ortholog  in  P.  berghei,  1562 
PBANKA_011110,  was  detected  in  gametocytes  [11].  In  order  to  characterize  this  1563 
protein  in  more  detail  we  have  generated  monoclonal  antibodies  specific  for  1564 






















41].  Three  non‐synonymous  SNPs  result  in  asparagine/aspartic  acid  dimorphisms  1580 
within  the  asparagine/aspartic  acid  stretch,  one  SNP  results  in  a  1581 




No  transcipt data  is  available  for PFF0620c except  for asexual blood  stages, where  1586 
transcript  levels  are  consistently  low  [42].  By  mass  spectrometry  the  protein  has  1587 
been detected in oocyst derived P. falciparum sporozoites [32]. But its ortholog in P.  1588 
berghei,  PBANKA_011110,  was  detected  in  gametocytes  [11].  To  further  assess  1589 
protein expression we used PFF0620c‐specific mouse mAbs for immunofluorescence  1590 
staining  of  different  parasite  stages  of  P.  falciparum.  Gametocytes,  from  stage  I  1591 
through to stage V (Figure 2A), as well as salivary gland derived sporozoites (Figure  1592 







MUSCLE (3.7) multiple sequence alignment 1596 
 1597 
pfal|PFF0620c           -----MHIVSFIIFFFALFFPI-----------SICY------------------KINGV 1598 
pcha|PCHAS_011170       -------MMKTYFWLAVHFFSS-----------FWMI------------------QNIEI 1599 
pber|PBANKA_011110      -------MMSIYFWVAIHIFSS-----------FWMI------------------QNIEI 1600 
pyoe|PY03099            -------MMRIYFWLAMHIFSS-----------FWMI------------------QNIEI 1601 
pviv|PVX_113780         --------------------------------------------------------MKGT 1602 
pkno|PKH_113610         MRVRHFSFLRLFLLLSLLVYHLPVQKQRHRSIPSWKYPDEGDDHPPQNAFSHMANQVKGI  1603 
 1604 
 1605 
pfal|PFF0620c           CDFSSEGLSLLPEEKLDF---------SVSRNVDKLSDENNVRHCVHFSKGFEYLRFICP 1606 
pcha|PCHAS_011170       CDFSKESLDVALTKDKSV---------IGNSSNEENHSDNNIKHCVKFTKGFEIFTFICP 1607 
pber|PBANKA_011110      CDFSRGSLDVALMNNKIL---------IDNNLKEENYNDNNIKHCVIFTKGLEIFTFICP 1608 
pyoe|PY03099            CDFSRDSLDVTLMNNKIV---------IDNNLKEENYNDNNIKHCVKFTKGLEIFTFICP 1609 
pviv|PVX_113780         CDFSRAPLNVSCSENEIVA-LPGGEGAMVSGTTGSTANDERARHCVQFTKGFDVLTFVCP 1610 
pkno|PKH_113610         CDFSRGPLNVSTTENEIVPLLVQAELHAGSAPLSDAHTDEPVQRCVQFTKGMEVLTFVCP  1611 
                        ****   *.:   :.  .           .    .   ::  ..** *:**:: : *:**  1612 
 1613 
pfal|PFF0620c           M--RKDNYEGIEIRPVECFEYIHI-EGREHKLSEILKGSLYEKSINDNIMTRDVFIPPTI 1614 
pcha|PCHAS_011170       KGNNNDNYNGIEIRPVQCFEKVRI-NGKEENLKDVLKGVITENKETDTSIIRKAFIPPTI 1615 
pber|PBANKA_011110      KGNNNDNYKGVEIRPEQCFEKVRI-NGKEENLKDILKGVVIEKKETDTEIIRKALIPPTI 1616 
pyoe|PY03099            KGNNNDNYKGIEIRPEQCFEKVRI-NGKEENLKDILKGVIIEKKETDTEIIRKAFIPPTI 1617 
pviv|PVX_113780         K-RSSEDYSGVEIRPMSCFETVRRTDGTNQQLSEVLKGVQLENRDTDLLSIRRVFIPPTI 1618 
pkno|PKH_113610         K-RNTEDYIGVEIRPMECFEKVRMHNGNKKKLNNVLKGVQLENIDTDSLSIRKVFIPPTI  1619 
                            .::* *:**** .*** :.  :* : :*.::***   *:  .*    * .:*****   1620 
 1621 
pfal|PFF0620c           YEDMFFECTCDNSLTFKNNMIGIRGIMKIHLKKNILYGCDFDH----------------- 1622 
pcha|PCHAS_011170       YNDMSFECSCDNSLTIKDNTIGARGIMRVHLKKNKIFGCDFNY----------------- 1623 
pber|PBANKA_011110      YQDMSFECSCDNSLTIKDNYIGARGIMKVHLKKNIIFGCDFNY----------------- 1624 
pyoe|PY03099            YQDMSFECSCDNSLTIKDNYIGARGIMKVHLKKNIIFGCDFNY----------------- 1625 
pviv|PVX_113780         YQNFIFECSCDNSLTFWKNKMGARGIMRVHLRRNILFGCDFDHTGGVEYTGGLGGELPMA 1626 
pkno|PKH_113610         YRNIIFECTCDNSLSFWNNKMGTRGIMRVHLRKNIVFGCDFDHRGGRENILEVEGELPAV  1627 
                        * :: ***:*****::..* :* ****.:**..* ::****::                    1628 
 1629 
pfal|PFF0620c           -----------------------------------------DEKLMKNKTAFTNFYDKQK 1630 
pcha|PCHAS_011170       --------------------------------------DASDTKFSNGKSAFTNFYDNQA 1631 
pber|PBANKA_011110      --------------------------------------DSNEPKLSNGKSAFAQFYDKQV 1632 
pyoe|PY03099            --------------------------------------DTNEPKHSNGKSAFARFYDKKI 1633 
pviv|PVX_113780         DEASVGSAYDRSAGGGSAEDRSAGGGSADDWAFWRNAGPSAEELAEKNKTAFTNFYPPGE 1634 
pkno|PKH_113610         DEA----------------NRNTTG----DWAFWRNAGPSAEELAERNKTAFSQFYTSEE  1635 
                                                                 :    ..*:**:.**       1636 
 1637 
pfal|PFF0620c           ILPLIGNNNNDDDNNDDDNNNDNNNNDNNNNNNNNNNNNNNNNNNNITCNVTIKKSQVYL 1638 
pcha|PCHAS_011170       I----------------------------------------DLNRSTVCNTEVNTKEVYL 1639 
pber|PBANKA_011110      V----------------------------------------DSNKNIICNTQVNNKEVYL 1640 
pyoe|PY03099            IV---------------------------------------NSNKNIICNTQVNSKEVYL 1641 
pviv|PVX_113780         VS--------------------------------------LAKEKGLVCDVKITKREVYL 1642 
pkno|PKH_113610         VN--------------------------------------DAKDKGIICNVKITKREVYL  1643 
                        :                                          :..  *:. :.. :***   1644 
 1645 
pfal|PFF0620c           GIICPDGYTLYPNDCFKNVIYDNNIIIPLKKIIPHDILYHQDKNK--RITFASFTLNINE 1646 
pcha|PCHAS_011170       GLVCPEGYEMYPENCFEYVLFES-NVVRINELIKHDVKLHIEKNKHTHMSFASFTLNPNE 1647 
pber|PBANKA_011110      GLVCPEGYGMYPENCFENVLFEK-KVINITELIKHDVKLHIEKNK--NISFASFILNPNE 1648 
pyoe|PY03099            GLVCPEGYEIYPENCFENILFEN-KVIKISELIKHDIKLHIEKNK--NISFASFILNSNE 1649 
pviv|PVX_113780         GLVCPPGYEMYPSNCFERVLQKDGSIVRVSELLKHDVSFHADGNR--RMSFATFTLNRNE 1650 
pkno|PKH_113610         GLVCPSGYEMYPSNCFDRVLYKD-SIVRMSELIKHHVTFHMDSNR--RMSFATFSLDRNE  1651 
                        *::** ** :**.:**. :: ..  :: :.::: * :  * : *.  .::**:* *: **   1652 
 1653 
pfal|PFF0620c           NPPGFTCYCIKDQTNINNPLIVNFHFSNQETSYATKNKNLFFYFIFIFPFLYVILLL 1654 
pcha|PCHAS_011170       NPKSFSCQCIK-KNANAFPLIANIMFSNYE-SYSFNYHVTYLILISIILISYI---- 1655 
pber|PBANKA_011110      NPKSFSCHCIK-NNDNSFPLIANITFSNYE-SYSFNFHVTYLILIFILLISYI---- 1656 
pyoe|PY03099            NPKSFSCHSQQIKSGNC----------------------LCISPIYINVNICK---- 1657 
pviv|PVX_113780         NPQGFSCMCLNVQAPEAPPLQANFAFHNYE-SAGVRFGLPCALVALVLLALCL---- 1658 
pkno|PKH_113610         NPPGFTCLCVRMDIPEAPPLQANFVYHNYE-SFGFHFRLLYVLVVILLLVLCL----  1659 
                        ** .*:* . . .                                 :            1660 
Figure 1. Amino acid  sequence alignment of PFF0620c with  its orthologs. Full‐length putative orthologs of P.  1661 
falciparum PFF0620c are found in the genomes of the human plasmodial species P. vivax  (PVX_113780) and P.  1662 
knowlesi  (PKH_116310) and  in  the genomes of  the  rodent plasmodial  species P.  chabaudi  (PCHAS_011170),  P.  1663 
berghei (PBANKA_011110) and P. yoellii (PY03099). Sequence identities are 37‐50%. "*"; identical, ":"; conserved  1664 







stage  I  gametocytes  and  expression  intensity  increased  marginally  during  1669 
gametocytogenesis.  1670 
Correspondingly, expression of PFF0620c  in different  life‐cycle stages was assessed  1671 
by Western blot analysis of cell lysates using anti‐PFF0620c specific mAbs (Figure 3).  1672 
With  gametocyte  lysate  a  discrete  38kDa  band  was  detected  (red  arrow),  1673 




case of  strain K1  (approximately 35kDa)  (blue arrow,  Figure 3A).  In K1  trophozoite  1678 
lysate an additional band of approximately 120kDa was detected (green arrow). The  1679 
38  and 35  kDa bands were not detected when proteins had been  reduced  (Figure  1680 
3C).  In  contrast,  the  120kDa  band  was  visible  under  reduced  and  non‐reduced  1681 
conditions.  In  lysate  of  salivary  gland  derived  sporozoites  no  band  was  detected.  1682 
Western blot analysis of asexual blood stage lysates with mAbs specific for Pfs48/45,  1683 
a marker for early gametocytes, indicated that asexual blood stage lysates of neither  1684 
the  gametocyte  producing  strain  3D7  nor  the  non‐producing  strain  K1  contained  1685 






Figure  2.  Detection  of  PFF0620c  expression  in  different  life‐cycle  stages  of  P.  falciparum  by  1689 
immunofluorescence  staining. Acetone‐methanol  fixed  stage  I,  II,  III,  IV  and V  gametocytes  (A),  asexual  blood  1690 









Figure  3:  Detection  of  PFF0620c  expression  in  different  life‐cycle  stages  of  P.  falciparum  by  Western  blot  1697 
analysis. Either reduced (C) or non‐reduced (A) protein lysates of gametocytes (G), asexual ring (R), trophozoite  1698 
(T) stages of either a gametocyte high producing strain  (3D7) or a non‐producer strain  (K1), and salivary gland  1699 
derived  sporozoites  (S) were probed  for  expression of PFF0620c by Western blot  analysis using anti‐PFF0620c  1700 
mAb c29. As positive control non‐transfected (‐) and PFF0620c‐expressing (+) HEK cell  lysates (HEK) were used.  1701 
Monoclonal antibodies specific for Pfs48/45 (early gametocyte marker), for CSP (sporozoite marker), or an anti‐ 1702 









specific  mAbs.  Our  immunofluorescence  staining  results  revealed  expression  of  1708 
PFF0620c  in  gametocytes,  sporozoites  and  schizonts.  Expression  was  highest  in  1709 
gametocytes, lower in sporozoites and borderline in schizonts. Accordingly a discrete  1710 
band  of  the  expected  size  was  detected  in  gametocyte  lysates  by  Western  blot  1711 
analysis. In asexual blood stage lysates of strain 3D7 a very weak band of the same  1712 
size was detected. This does not correlate  to  immunofluorescence staining  results,  1713 
where only a very faint staining of schizonts was observed. Contamination of asexual  1714 
blood  stage  lysate  with  gametocytes  could  be  excluded,  as  western  blot  with  an  1715 
early gametocyte marker was negative. Interestingly in asexual blood stages of strain  1716 








lysate  of  strain  K1  is  also  detected with  reduced  lysate,  suggesting  that  this  band  1725 
derives  from  PFF0620c  non‐related  cross  reactivity.  In  sporozoites  PFF0620c  was  1726 
detected  by  immunofluorescence  staining  but  not with western  blot  analysis. One  1727 
possible explanation could be that the sporozoite lysate was too diluted. This could  1728 
hold  true  even  though  we  aimed  for  equal  loading  of  total  protein  for  lysates  of  1729 
different  parasite  stages,  as  this  preparation  is  a  crude  extract  from  mosquito  1730 
salivary glands, not only  containing  sporozoites. Discrepancies  in Western blot and  1731 
immunofluorescence  results  could  be  explained  by  PFF0620c‐unrelated  1732 








PFF0620c  and  its  tandem  pair  Pfs12  (PFF0615c)  are  expressed  at  different  time  1738 
points  of  the  parasite  life  cycle;  PFF0620c  being mainly  expressed  in  gametocytes  1739 
and  sporozoites,  whereas  Pfs12  is  expressed  in  merozoites  [3,5].  This  shows  that  1740 
expression of  tandem‐arranged genes encoding 6‐cystein proteins  is not coercively  1741 
co regulated.  1742 
PFF0620c is a highly conserved protein; among 17 strains only five non‐synonymous  1743 
single  nucleotide  polymorphisms  were  identified  in  the  PFF0620c  encoding  1744 
sequences  [39‐41]. Three of  them are asparagine/aspartic acid dimorphisms within  1745 
the asparagine/aspartic acid stretch and one  is positioned at the C‐terminus of  the  1746 
GPI‐attachment  signal  sequence.  Therefore  the  only  SNP  possibly  having  1747 
conformational or functional effects is the glutamic acid (negatively charged)/lysine  1748 
(positively  charged)  dimorphism  within  the  N‐terminal  s48_45  domain.  High  1749 
sequence conservation could speak for absence of immune pressure on PFF0620c or  1750 
alternatively  for  a  function  of  PFF0620c  requiring  high  conservation.  In  case  that  1751 
continuative research identifies PFF0620c as target of protective immune responses,  1752 
rendering  PFF0620c  a  potential  vaccine  antigen,  low  polymorphism  would  reduce  1753 
the risk of allele specific resistance.  1754 
As expression of PFF0620c was detected  in gametocytes and salivary gland derived  1755 
sporozoites,  it  is highly probable  that  the protein  is also expressed  in  intermediate  1756 
stages,  meaning  gametes,  ookinetes  and  oozysts.  Therefore  possible  functions  of  1757 
PFF0620c  comprise  fertilization,  penetration  of  mosquito  gut  lining,  sporozoite  1758 









P.  falciparum  strain  3D7 was  cultured essentially  as  described previously  [44].  The  1764 
culture medium was  supplemented with 0.5% AlbuMAX  (Gibco) as a  substitute  for  1765 
human  serum  [45].  Cultures  were  synchronized  by  sorbitol  treatment  [46].  1766 




For  indirect  immunofluorescence microscopy, smears of  infected red blood cells or  1771 
air‐dried  salivary  gland  sporozoites  (P.  falciparum  strain  NF54)  attached  to  1772 
microscope slides were fixed in 60% methanol and 40% acetone for 2 min at −20°C  1773 
and blocked with 1% BSA  in PBS. Cells were probed with  the  following primary or  1774 
secondary  antibodies:  unlabeled  or  biotin‐labeled  mouse  anti‐PFF0620c  mAb  c29  1775 
[48], mouse anti‐CyRPA mAb c06, mouse anti‐CSP mAb EP9  [49], Alexa488‐labeled  1776 
mouse  anti‐GAPDH  1.4a mAb  [50],  anti‐Pfs25  rabbit  serum  (obtained  through  the  1777 
Malaria Research and Reference Reagent Resource Center MR4 (MRA‐38), deposited  1778 
by  C.  Gowda),  Alexa568‐labeled  donkey  anti‐mouse  IgG  (Invitrogen),  Alexa568‐ 1779 
labeled  streptavidin  (Invitrogen)  and  FITC‐labeled  goat  anti‐rabbit  IgG.  Slides were  1780 
mounted in mounting medium containing DAPI (ProLong Gold antifade reagent with  1781 
DAPI,  Invitrogen).  Fluorescence  microscopy  was  performed  on  a  Leica  DM‐5000B  1782 
using  a  60x  oil  immersion  objective  lens  and  documented  with  a  Leica  DFC300FX  1783 
digital  camera  system.  Images  were  processed  using  Leica  Application  Suite  and  1784 
Adobe Photoshop® CS3.  1785 
Western  blot  analysis  of  P.  falciparum  blood  stages,  sporozoites  and  1786 
transfected HEK cells  1787 
Parasite  and  HEK  cell  lysates  were  prepared  and  western  blot  was  performed  as  1788 
described previously [33]. Membranes were probed with the following primary and  1789 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infections  are  caused  by  microbes.  It  was  Luis  Pasteur  who  started  to  rationally  1978 
develop  vaccines  by  generalizing  Jenner's  idea  to  the  basic  principle:  isolation,  1979 
inactivation  and  injection  of  the  causative  agent  [3].  Following  these  principles,  1980 
vaccines against  rabies, polio, measles, mumps and rubella were developed.  In  the  1981 
course of the 20th century another strategy, the so‐called ‘subunit vaccine approach’,  1982 
was  applied  for  the  development  of  vaccines,  mainly  against  bacterial  infections.  1983 
Isolation,  inactivation  and  injection  of  bacterial  toxins  ensued  vaccines  against  1984 
diphtheria and tetanus. In contrast, for vaccines against Streptococcus pneumoniae,  1985 
Neisseria  meningitidis,  Haemophilus  influenzae,  among  others,  capsular  1986 
polysaccharides were applied. These and other vaccines allowed protection against  1987 
many  once  lethal  diseases.  Together  with  the  discovery  of  antibiotics,  these  1988 
developments  are  THE  milestones  in  the  history  of  medicine.  However,  for  some  1989 
infectious diseases these conventional approaches have so far not been crowned by  1990 
success.  Consequently,  new  approaches  for  vaccine  development  need  to  be  1991 
considerer. Remarkable progress was achieved by the introduction of adjuvants and  1992 






Reverse  Vaccinology;  a  prospective  for  malaria  vaccine  1996 
development.  1997 
Sequencing of the entire genome of infectious agents now suddenly gives full access  1998 
to  all  the proteins  that  a microorganism  can potentially  encode.  The  genome as  a  1999 
whole can therefore be screened, using bioinformatics approaches, to identify genes  2000 
with  the  desired  properties.  This  approach,  referred  to  as  reverse  vaccinology,  is  2001 
expected to identify vaccine targets in a more rational and faster way compared to  2002 
traditional  methodologies  [4].  Criteria  to  select  hypothetical  proteins  from  the  2003 
genome  for  subsequent experimental  assessment are  versatile  and depend on  the  2004 
disease  and  the  type  of  vaccine  that  is  aspired.  Possible  selection  criteria  include  2005 
surface  expression,  homology  to  known  targets  of  protective  immunity  or,  more  2006 
generally,  the  prediction  of  being  implicated  in  motility,  adhesion,  invasion,  2007 
secretion,  signalling,  immune  evasion  or  toxicity.  Integrating  comparative  genome  2008 
analysis may further help to identify candidates associated with virulence, which are  2009 
conserved  among  the  pathogen  population  or  have  no  homology  to  self‐antigens.  2010 
Additional  criteria  could  incorporate  information  from  functional  genomics,  like  2011 
transcription  analysis  or  from  proteomics.  The  prime  example,  demonstrating  the  2012 
potential  of  reverse  vaccinology,  was  the  development  of  a  novel  vaccine  against  2013 
Neisseria meningitidis serogroup B by Chiron (now Novartis) launched in 2000 [5,6].  2014 
Using  computer  analysis,  hypothetical  cell‐surface  proteins  or  homologs  of  known  2015 
proteins associated with virulence and pathogenesis were selected  from the entire  2016 
genome.  These  hypothetical  proteins  were  recombinantly  expressed,  purified  and  2017 
used to immunize mice. Immune sera were then tested in ELISA, FACS and Western  2018 
blot  analysis  in  order  to  confirm  their  surface‐exposure.  Immune  sera  were  also  2019 
tested  in  complement‐mediated  bactericidal  assays  for  protective  activity.  Finally,  2020 
positive hits were tested for presence and conservation in a panel of N. meningitidis  2021 
variants  [7].  In  the  end,  the  five  most  promising  candidates  were  combined  for  2022 





Decades  of  malaria  research  have  identified  only  a  few  promising  vaccine  2025 
candidates. To date,  solely  two vaccines were able  to  induce up  to 50% protective  2026 
efficacy [9,10]. This clearly is a milestone in malaria research, but, on the other hand,  2027 
it  is  an  anticlimax  considering  the  invested  time  and  efforts.  Explanations  for  the  2028 









prerequisite  for  the  elucidation  of  the  P.  falciparum  transcriptome  and  proteome  2038 
[13–18]. Together, this information presents an opportunity to use high throughput  2039 
approaches to identify novel vaccine antigens. There are a few studies that applied  2040 
the  principle  of  reverse  vaccinology  for  malaria  [19].  Intended  as  a  community  2041 
resource to aid malaria vaccinologists, a database (MalVac) containing information of  2042 
known  vaccine  candidates  and  predicted  adhesins  was  established  [20].  The  2043 
database houses  information on 161 P.  falciparum proteins  that were analysed  for  2044 
features important from the view of vaccinology; predictions for orthologs, paralogs,  2045 
transmembare  topologies,  beta  helix  supersecondary  structural motifs,  subcellular  2046 
localization,  similarity with  human proteins,  antigenic  regions,  conserved  domains,  2047 
B‐  and  T‐cell  epitopes  and  allergens  are  summarized  [20].  There  are  at  least  two  2048 
studies  applying  the  combination  of  proteomics  and  serological  analysis  known  as  2049 
SERPA  (serological  proteome  analysis)  for  identification  of  novel  potential  vaccine  2050 
candidates. Doolan et al. used a protein microarray spotted with 250 P. falciparum  2051 
proteins  expressed  in  an  E.  coli  based  cell‐free  in  vitro  transcription/translation  2052 
system  to  test  human  sera  from  volunteers  immunized  with  radiation‐attenuated  2053 






used  a  protein  microarray  spotted  with  1204  proteins  selected  based  on  stage‐ 2057 
specific  expression,  subcellular  localization,  secondary  protein  structure  or  2058 
documented immunogenicity to analyze sera from malaria exposed Malian children  2059 
[22].  For  49  proteins  antibody  reactivity  was  significantly  higher  in  protected  vs.  2060 
susceptible children. These included the vaccine candidates STARP, LSA‐1 and RESA  2061 
but  did  not  include  MSP‐1,  MSP‐2,  AMA‐1,  LSA‐3  or  CSP.  Furthermore,  available  2062 
genome, transcriptome and proteome data was used to identify protein function or  2063 
to  identify  subsets  of  proteins  likely  to be  involved  in merozoite  invasion or  to be  2064 
merozoite  surface  proteins  [23–25].  Although  all  these  studies  identified  proteins  2065 
with  highly  interesting  attributes  for  malaria  vaccine  antigens,  studies  did  not  2066 
progress  to  evaluate  whether  these  proteins  indeed  are  targets  of  protective  2067 
immunity. And that presents  the crux of  the matter; eventually candidate antigens  2068 
need to be tested experimentally for their potential of inducing protective immunity.  2069 
Consequently,  the  success  of  reverse  vaccinology  stands  and  falls  with  the  2070 
availability of a medium‐throughput system to test  for protective  immunity, which,  2071 
most critically, has to correlate with protection in humans. Although various in vitro  2072 





novel  malaria  vaccine  antigens.  From  the  P.  falciparum  genome  we  selected  2078 
potential  targets  of  protective  humoral  immunity,  meaning  hypothetical  proteins  2079 
predicted  to be on  the  surface of  extracellular parasite  stages. More precisely, we  2080 
selected  proteins  predicted  to  encode  an  N‐terminal  secretion  signal  and  a  C‐ 2081 
terminal GPI‐attachment signal. From these we selected based on transcriptome and  2082 
proteome data proteins with specific expression in one of the extracellular parasite  2083 














on  the  protein  this  may  include  in  vitro  assays  for  asexual  growth  inhibition,  2095 
merozoite invasion inhibition, sporozoite invasion inhibition, inhibition of sporozoite  2096 
gliding motility or in vivo passive immunisation and transmission blocking assays.  2097 
Most  reverse  vaccinology  approaches  involve  recombinant  expression  of  in  silico‐ 2098 
selected  candidates  in  E.  coli  or  E.  coli‐based  cell‐free  in  vitro  expression  systems  2099 
either  for  the  generation  of  specific  immune  sera,  or  as  probe  for  protein  2100 
microarrays  to  analyze  immune  sera  [21,22].  Rather  unproblematic  for  bacterial  2101 
pathogens,  recombinant  expression  of  plasmodial  proteins  in  E.  coli  can  be  2102 
troublesome  as  proteins  may  not  be  folded  or  glycosylated  appropriately.  This  is  2103 
especially  problematic  for  surface  proteins,  which  are  prone  to  contain  complex  2104 
folds with  numerous  disulfide  bonds  and  glycosylation  sites.  The  use  of misfolded  2105 
proteins  for  immunisation  may  lead  to  induction  of  antibodies  incapable  of  2106 
recognizing  the  endogenous  protein,  or  to  non‐reactivity  when  used  for  the  2107 
assessment of human immune sera resulting, in both cases, in false negative results.  2108 
To  overcome  this  difficulty,  we  developed  a  eukaryotic,  cell‐based  expression  2109 
system,  which  expresses  recombinant  proteins  on  eukaryotic  cell  surfaces  [26].  2110 
Thereby, we favoured correct folding of the protein. We used these expressing cells  2111 
to  immunize mice as well as  for  selection of  specific monoclonal antibodies, which  2112 
entailed generation of antibodies  specific  for  conformational epitopes and capable  2113 
of  binding  to  the  endogenous  protein  in  native  conformation.  Such  high  quality  2114 
antibodies are pivotal for functional in vitro or in vivo analysis. For three hypothetical  2115 





monoclonal  antibodies  recognize  conformational  epitopes.  A  great  outcome  2118 
considering  the  complex  folding  of  PFF0620c,  a  member  of  the  6‐cystein  protein  2119 
family,  as  well  as  for  PFD1130w/CyRPA  which  contains  12  cysteine  residues.  The  2120 
significance of our strategy is demonstrated by the fact that, in contrast to sera from  2121 
mice  immunised  with  purified  recombinant  CyRPA  produced  in  E.  coli  (data  not  2122 
shown),  anti‐CyRPA  antibodies  generated  by  immunisation  and  selection  with  2123 
surface‐expressing eukaryotic cells showed parasite growth inhibitory activity.  2124 
Although  time  consuming  to  generate,  using  monoclonal  antibodies  rather  than  2125 
polyclonal immune sera for functional assays offers the advantage of discriminating  2126 
functionality of  antibodies  specific  for particular  epitopes.  This  can be of  immense  2127 
impact,  as  the  functional  activity  of  antibodies  can  largely  depend  on  their  fine  2128 
specificity.  This  has  been  shown  for  the  growth  inhibitory  activity  of  antibodies  2129 
specific for the blood stages antigens MSP‐1 and AMA‐1 [27,28]. Akin, we found that  2130 
antibodies specific for CyRPA can be growth inhibitory or neutral depending on their  2131 





series  of  in‐silico  predicted  candidates  still  await  generation  of  specific  antibodies.  2137 
For  two  candidates,  the  merozoite  protein  PF14_0325  and  the  gametocyte  and  2138 
sporozoite expressed 6‐cysteine protein PFF0620c, characterization is ongoing. For a  2139 




falciparum  stages.  Thereby,  we  hope  to  increase  the  choice  of  vaccine  antigens  2144 





Immunodominant  versus  conserved;  implications  for malaria  2147 
vaccine development.  2148 
Malaria parasites are highly polymorphic [29–31]. The underlying mechanism is the  2149 
coevolutionary  “arms  race”  between  the  host’s  immune  system  and  the  evasion  2150 
strategies of  the parasite, which has  left  characteristic  traces of  selection  in either  2151 
genome. Proteins under immune pressure can undergo natural balancing selection,  2152 
meaning  frequency‐dependent  selection  with  a  rare‐allele  advantage,  leading  to  2153 
extensive  sequence  polymorphisms  [32].  Especially  parasite  proteins  that  are  2154 
accessible to the host immune system, mainly proteins expressed on the surface of  2155 
the extracellular  stages or proteins  transported  to  the  surface of  the host  cell,  are  2156 
highly  polymorphic  [30,33].  Current  malaria  blood  stage  vaccine  antigens  are  2157 
merozoite  surface  proteins  or  proteins  secreted  from  apical  secretory  organelles  2158 
upon  invasion.  Hardly  surprising,  these  proteins  mostly  comprise  substantial  2159 
polymorphisms  [34].  Extensive  polymorphism  has  been  observed  for  MSP‐1  in  2160 
isolates from different geographical areas. Its gene has a mosaic and heterogeneity  2161 
structure  with  allelic  recombination  demonstrated  in  isolates  from  different  2162 
countries  [35].  However,  reduced  nucleotide  diversity  was  noted  in  a  region  2163 
encoding  the 19‐kDa C‐terminal epidermal growth  factor‐like domain, a prominent  2164 
vaccine target  [35].  In contrast,  for AMA‐1 all of  the sequence diversity  is  found  in  2165 
the  form  of  SNPs.  The  analysis  of  506  human  P.  falciparum  infections  in  Mali  2166 
identified 214 unique AMA‐1 haplotypes  [36].  In  contrast,  the  asexual  blood  stage  2167 
antigen  CyRPA  identified  in  this  thesis  is  highly  conserved;  DNA  sequencing  of  a  2168 
selection of 18 P. falciparum strains from different geographic regions identified only  2169 
two  distinct  CyRPA  haplotypes  differing  by  a  single  amino  acid  dimorphism.  2170 
Furthermore  we  could  demonstrate  that  variants  are  likewise  affected  by  growth  2171 
inhibitory  anti‐CyRPA  mAbs,  indicating  that  this  dimorphism  is  of  no  functional  2172 
importance.  2173 







that  antibody  responses  are  allele‐specific  and  associated with  protection  [37,42– 2178 
44].  As  a  result,  genome‐wide  analysis  for  signatures  of  balancing  selection  is  2179 
thought  to  discover  new  vaccine  candidates  [33,41,45,46].  In  contrast  to  the  2180 
approach of  identifying  immunodominant antigens by the analysis of  immune sera,  2181 
this  strategy  offers  the  advantage  of  identifying  those  immunodominant  antigens,  2182 
which  truly  are  targets  of  protective  immune  mechanisms.  However,  as  immune  2183 
selection acts upon phenotypic variation ‐ a product not solely of allelic variation but  2184 
also epigenetic  regulation of  transcription or  translation  ‐  this approach potentially  2185 
misses  some  protective  antigens  [46].  In  the  case  of  CyRPA  we  identified  strong  2186 
conservation although it is a target of protective antibodies. This could indicate that  2187 
either CyRPA does not experience selective pressure or that other evasion strategies,  2188 
which  do  not  involve  diversification  apply  for  this  protein.  Features  of  CyRPA  2189 
indicating  its moderate  immunogenicity  are  the  rather  low CyRPA‐specific  titres of  2190 
sera of malaria exposed individuals and its presumably low abundance; western blot  2191 
or  immunofluorescence‐staining  signals with  specific  antibodies were  of moderate  2192 
intensity  compared  to  major  merozoite  proteins.  Furthermore,  in  released  2193 




entirely  blocked by  the  antibodies.  But  as P.  falciparum was described  to  relay on  2198 
redundant  invasion  pathways,  we  cannot  exclude  that  the  antibody  mediated  2199 




Although  proteins  under  balancing  selection  are  likely  to  be  targets  of  protective  2204 
immune responses, they consequently may be problematic for the development of a  2205 
broadly  effective  vaccine.  Immunisation  with  a  certain  variant  potentially  induces  2206 




parasite  population.  Besides  being  only  partly  effective,  vaccination  with  a  single  2208 
allele could lead to an increased frequency of variants not targeted by the vaccine, as  2209 
was observed with pneumococcal vaccines; following the introduction of the seven‐ 2210 
valent  conjugate  pneumococcal  vaccine  (PCV7)  higher  colonisation  and  invasion  2211 
rates of non‐vaccine serotypes emerged [50,51].  In the case of malaria, results of a  2212 
phase  2  trial  of  a multi‐antigen  blood  stage  vaccine  detected  selection  for  clinical  2213 
infections with non‐vaccine type variants [52]. The issue of vaccine resistant malaria  2214 
may  possibly  be  resolved  by  including  several  alleles  into  a  multivalent  vaccine  2215 
formulation or by designing chimeric antigens eliciting cross‐reactive responses [53].  2216 
Such  an  approach  would  not  be  required  for  a  vaccine  based  on  the  conserved  2217 
CyRPA, which would likely target the entire parasite population.  2218 
A way to overcome the problems associated with antigenic diversity may be to rely  2219 
on  new  vaccine  targets  like  CyRPA  that  are  more  conserved.  But  why  may  some  2220 
targets  of  protective  immune  responses  be  conserved?  One  reason  can  be  that  2221 
binding  sites of  surface  ligands must have a  limited scope of variability  in order  to  2222 
remain  capable  of  binding  to  their  receptors.  Furthermore,  as  a  mechanism  of  2223 
immune evasion conserved antigens seem to be selected by evolution to be poorly  2224 
immunogenic. Molecular  reasons behind  the poor  immunogenicity are not entirely  2225 
clear.  Besides  being  of  low  abundance,  considered  mechanisms  are  that  certain  2226 
conserved epitopes cannot be recognized by the B or T cell germline repertoire, or  2227 
that epitopes are hard to reach [54,55]. For other infectious diseases with the issue  2228 
of  immune evasion,  like HIV and  influenza, conserved protective epitopes could be  2229 
identified.  Universal  neutralizing  antibodies  have  been  isolated  against  the  2230 
conserved region of hemagglutenin of  influenza [56]. However, such antibodies are  2231 
rare, have low affinity, and cannot be induced in large quantities during infection or  2232 
vaccination  [57]. Akin, a broadly neutralizing monoclonal antibody against  the CD4  2233 
binding  site  of  the  HIV  envelope  protein  gp120  has  been  identified  [58].  Yet,  the  2234 
antibody  was  shown  to  bind  the  epitope  only  with  its  heavy  chain,  because  the  2235 





Cryptic  antigens/epitopes  can  only  be  useful  for  vaccine  development  if  a  2238 
qualitatively  or  quantitatively  superior  immune  response  can  be  induced  upon  2239 
vaccination compared to natural infection. Different strategies to convert conserved  2240 
immunosilent epitopes into immunodominant ones have been described [60–64]. If  2241 
presented  in  a  non‐natural  configuration,  cryptic  epitopes  can  sometimes  induce  2242 
immune  responses  that  surprisingly  can  recognize  the  native  protein  [63,64].  For  2243 
example,  invasion‐blocking  antibodies  are  induced  by  an  immunologically  cryptic  2244 
epitope located in the N‐terminal region of CSP, but only when it is presented in the  2245 
absence  of  the  immunodominant  rest  of  the  protein  [62].  On  the  other  hand  2246 
immunisation  with  chimeric  peptides  was  necessary  to  induce  immune  responses  2247 
that  target  certain otherwise cryptic motifs of MSP2, CSP and TRAP  [60,61].  In  the  2248 
studies  described  here,  monoclonal  antibodies  specific  for  CyRPA  inhibited  2249 
merozoite  invasion  depending  on  their  unique  specificity.  These  antibodies  were  2250 




of  protein  surface  loops  comprising  primarily  epitopes  associated  with  protection  2255 
[65].  2256 
Prospects of parasite growth inhibitory vaccines.  2257 
Potential  of  the  P.  falciparum  NOD/scid‐IL2Rγnull  mouse  model  for  2258 
assessment of antibody‐mediated effector mechanisms.  2259 
The  identification  of  robust  correlates  of  protection  and  assays  that  measure  2260 
functionally  relevant  immune  responses  will  be  of  enormous  benefit  for  the  2261 
development  of malaria  vaccines. We  describe  for  the  first  time  the  use  of  the P.  2262 
falciparum NOD/scid‐IL2Rγnull mouse model  for antibody transfer experiments. This  2263 
model produces very consistent and reproducible  infections with P. falciparum and  2264 







inhibition  measured  in  the  P.  falciparum  SCID‐mouse  model  can  be  translated  to  2269 
human  P.  falciparum  infections.  The  assessment  of  the  predictive  potential  is  a  2270 
crucial step towards the use of results generated by this model as surrogate marker  2271 




In  in  vitro  assays  malaria  blood  stage‐specific  antibodies  were  demonstrated  to  2276 
interfere with  parasite  growth  by  various modes  of  action.  Antibodies  specific  for  2277 
merozoite  surface  proteins  were  shown  to  not  only  block merozoite  invasion  but  2278 
also  to  mediate  agglutination  of  merozoites  or  to  induce  monocytes  to  release  2279 
mediators  that  block  division  of  intraerythrocytic  parasites  [66–68].  Furthermore,  2280 
antibodies  bound  to  infected  erythrocytes  or  free  merozoites  were  measured  to  2281 
induce phagocytosis, neutrophil respiratory bursts or activation of the complement  2282 
system  [69–73].  In  addition,  antibodies  specific  for  PfEMP1 were  demonstrated  to  2283 
block  resetting  and  sequestration  of  infected  erythrocytes  to  endothelial  cells  2284 
[74,75]. Hence, an interesting question left unanswered is whether the P. falciparum  2285 
NOD/scid‐IL2Rγnull  mouse  model  can  be  used  for  the  assessment  of  the  various  2286 




We  demonstrated  in  our  in  vitro  studies  that  antibodies  specific  for P.  falciparum  2291 
CyRPA  protein  can  inhibit  asexual  parasite  growth  by  interfering  with  merozoite  2292 
invasion.  However,  the  predictive  potential  of  in  vitro  functional  assays,  including  2293 
growth inhibition assays with antibodies, for human malaria infection is ambiguous.  2294 
Criticism  has  been  raised  after  field  trials  with  vaccine  formulations  that  induced  2295 
antibodies  capable  of  inhibiting  in  vitro  growth  but  failed  at  conferring  protection  2296 




immune  individuals  transferred  to non‐immune  individuals  induced a  rapid drop  in  2298 
parasitemia and vanishing of clinical symptoms. However, the transferred antibodies  2299 
that conferred protection inhibited in vitro parasite growth only in cooperation with  2300 
human  monocytes  [78].  These  findings  cast  doubts  on  the  relevance  of  in  vitro  2301 
growth  inhibitory  activity  of  antibodies  by  themselves  for  in  vivo  protection.  2302 
Recently, the relationship between P. falciparum growth rates in humans and in vitro  2303 
growth  inhibition  activity was  assessed. Malaria‐naive  volunteers were  immunised  2304 
with AMA1‐C1 adjuvanted with Alhydrogel, CPG 7909 and subsequently challenged  2305 
by  intravenous  inoculation with P.  falciparum  infected  erythrocytes  [79].  Although  2306 
no clinically relevant vaccine effect was observed in the small numbers of subjects in  2307 
this study, a significant association between  in vivo parasite multiplication rate and  2308 
vaccine‐induced  in  vitro  growth  inhibitory  activity  was  observed.  This  is  the  first  2309 
evidence that the  in vitro assay of parasite growth inhibitory activity can be a valid  2310 
surrogate marker  for malaria  vaccine  efficacy  in  the  selection  of  candidate  blood‐ 2311 
stage vaccines. Consequently,  invasion  inhibitory antibodies specific  to other blood  2312 
stage antigens,  like CyRPA, may also have an  impact on parasite growth  in human  2313 
infections.  2314 
If antibodies specific for CyRPA can be shown to control parasitmia in humans, too,  2315 
such  antibodies  could  theoretically  be  used  as  therapeutics  for malaria.  However,  2316 
antibody‐based  therapeutics  are  considered  too  expensive  for  malaria,  a  disease  2317 
mainly affecting poor populations. Antibody‐based therapeutics currently undergo a  2318 
revival  and  thereby  entailed  major  technical  advances  in  antibody  design  and  2319 
production  [83].  But  even  if  costs  are  brought  down  substantially,  antibody‐based  2320 
therapies  are  unlikely  to  be  applicable  as  standard  treatment  of  malaria.  But  2321 
antibody‐based  prophylaxis  for  non‐immune  individuals  travelling  to  affected  2322 
countries might be realizable. Appliance of CyRPA‐specific mAbs for prophylaxis may  2323 
only  be  possible  if  antibodies  prove  to  prevent  establishment  of  blood  stage  2324 
infection after  an  infectious mosquito bite.  In  comparison  to  antimalarials,  passive  2325 












antibody  in  the  mg/ml  range.  For  most  human  vaccines  specific  antibody  2335 
concentrations  from  <1  ug/ml  to  ~200  ug/ml  are  sufficient  to  confer  protection.  2336 





host.  But  since  the  parasite  growth  rate may  be  different  in  the  human  infection  2342 
compared to the mouse model the specific efficacy of inhibitory antibodies may also  2343 
differ. Furthermore, polyclonal antibodies induced by active immunisation may have  2344 
higher  affinities  compared  to  monoclonal  antibodies.  Hence,  vaccine  induced  2345 
antibody  concentration  required  for  protection  of  humans may  be  lower  than  the  2346 
concentration  of  mAbs  required  for  growth  inhibition  in  the  SICD‐mouse  model.  2347 
Furthermore  our  mouse  experiments  showed  that  parasite  density  influences  the  2348 
growth‐inhibitory effect of anti‐CyRPA antibodies. Deducing a similar association  in  2349 












candidates.  Our  strategy  was  based  on  the  selection  of  hypothetical  parasite  2354 
proteins that are accessible to the host immune surveillance by antibodies, and their  2355 
subsequent  functional  characterization  using  specific  monoclonal  antibodies.  Our  2356 
findings lead to the following key conclusions:  2357 




2. One of the characterized candidate proteins, CyRPA,  is  the target of growth  2362 
inhibitory  antibodies.  Together  with  its  high  sequence  conservation,  this  2363 
renders  CyRPA  a  potential  subunit  component  for  a  malaria  blood  stage  2364 
vaccine.  2365 
3. As  at  least  one  selected protein  candidate proved  indeed  to be  a  target  of  2366 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